

Arnold Ganser

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8861278/publications.pdf>

Version: 2024-02-01

725
papers

35,237
citations

6250

80
h-index

4338

173
g-index

736
all docs

736
docs citations

736
times ranked

30883
citing authors

#	ARTICLE	IF	CITATIONS
1	Genomic Classification and Prognosis in Acute Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2016, 374, 2209-2221.	13.9	3,067
2	Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. <i>Lancet</i> , The, 2004, 364, 141-148.	6.3	2,065
3	Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. <i>New England Journal of Medicine</i> , 2017, 377, 454-464.	13.9	1,628
4	Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2008, 358, 1909-1918.	13.9	1,514
5	Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia. <i>New England Journal of Medicine</i> , 2013, 369, 111-121.	13.9	1,284
6	Intracoronary Bone Marrow Cell Transfer After Myocardial Infarction. <i>Circulation</i> , 2006, 113, 1287-1294.	1.6	936
7	Monitoring of Bone Marrow Cell Homing Into the Infarcted Human Myocardium. <i>Circulation</i> , 2005, 111, 2198-2202.	1.6	888
8	Reduced Treatment Intensity in Patients with Early-Stage Hodgkin's Lymphoma. <i>New England Journal of Medicine</i> , 2010, 363, 640-652.	13.9	824
9	TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. <i>Blood</i> , 2012, 119, 2114-2121.	0.6	553
10	Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate- or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. <i>Journal of Clinical Oncology</i> , 2011, 29, 1987-1996.	0.8	514
11	Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase II study. <i>Lancet Oncology</i> , The, 2009, 10, 489-500.	5.1	458
12	Naturally Occurring Human Urinary Peptides for Use in Diagnosis of Chronic Kidney Disease. <i>Molecular and Cellular Proteomics</i> , 2010, 9, 2424-2437.	2.5	434
13	Cdkn1a deletion improves stem cell function and lifespan of mice with dysfunctional telomeres without accelerating cancer formation. <i>Nature Genetics</i> , 2007, 39, 99-105.	9.4	399
14	The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. <i>Blood</i> , 2011, 117, 2137-2145.	0.6	392
15	Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. <i>Blood</i> , 2012, 119, 3578-3584.	0.6	391
16	Monitoring of Minimal Residual Disease in NPM1-Mutated Acute Myeloid Leukemia: A Study From the German-Austrian Acute Myeloid Leukemia Study Group. <i>Journal of Clinical Oncology</i> , 2011, 29, 2709-2716.	0.8	355
17	Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation. <i>Blood</i> , 2014, 124, 3441-3449.	0.6	350
18	RUNX1 Mutations in Acute Myeloid Leukemia: Results From a Comprehensive Genetic and Clinical Analysis From the AML Study Group. <i>Journal of Clinical Oncology</i> , 2011, 29, 1364-1372.	0.8	349

#	ARTICLE	IF	CITATIONS
19	Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity. <i>Blood</i> , 2011, 117, 2469-2475.	0.6	341
20	Expression of the miR-17-92 polycistron in chronic myeloid leukemia (CML) CD34+ cells. <i>Blood</i> , 2007, 109, 4399-4405.	0.6	333
21	How I treat the acquired von Willebrand syndrome. <i>Blood</i> , 2011, 117, 6777-6785.	0.6	292
22	Intracoronary bone marrow cell transfer after myocardial infarction: 5-year follow-up from the randomized-controlled BOOST trial. <i>European Heart Journal</i> , 2009, 30, 2978-2984.	1.0	286
23	Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. <i>Blood</i> , 2017, 129, 1753-1762.	0.6	278
24	Prognostic Significance of <i>ASXL1</i> Mutations in Patients With Myelodysplastic Syndromes. <i>Journal of Clinical Oncology</i> , 2011, 29, 2499-2506.	0.8	258
25	Specific inhibition of bcr-abl gene expression by small interfering RNA. <i>Blood</i> , 2003, 101, 1566-1569.	0.6	251
26	How I treat refractory and early relapsed acute myeloid leukemia. <i>Blood</i> , 2015, 126, 319-327.	0.6	245
27	Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML. <i>Blood</i> , 2018, 132, 1703-1713.	0.6	237
28	Tumor suppressor genes in normal and malignant hematopoiesis. <i>Oncogene</i> , 2002, 21, 3475-3495.	2.6	230
29	Impact of <i>IDH1</i> R132 Mutations and an <i>IDH1</i> Single Nucleotide Polymorphism in Cytogenetically Normal Acute Myeloid Leukemia: SNP rs11554137 Is an Adverse Prognostic Factor. <i>Journal of Clinical Oncology</i> , 2010, 28, 2356-2364.	0.8	229
30	Precision oncology for acute myeloid leukemia using a knowledge bank approach. <i>Nature Genetics</i> , 2017, 49, 332-340.	9.4	229
31	Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD. <i>Blood</i> , 2019, 133, 840-851.	0.6	228
32	High <i>EVI1</i> Expression Predicts Outcome in Younger Adult Patients With Acute Myeloid Leukemia and Is Associated With Distinct Cytogenetic Abnormalities. <i>Journal of Clinical Oncology</i> , 2010, 28, 2101-2107.	0.8	222
33	A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy. <i>Haematologica</i> , 2012, 97, 393-401.	1.7	219
34	Clinical, Molecular, and Prognostic Significance of WHO Type <i>inv(3)(q21q26.2)/t(3;3)(q21;q26.2)</i> and Various Other 3q Abnormalities in Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2010, 28, 3890-3898.	0.8	217
35	Human $\gamma\delta$ T cells are quickly reconstituted after stem-cell transplantation and show adaptive clonal expansion in response to viral infection. <i>Nature Immunology</i> , 2017, 18, 393-401.	7.0	208
36	G-CSF as immune regulator in T cells expressing the G-CSF receptor: implications for transplantation and autoimmune diseases. <i>Blood</i> , 2003, 102, 734-739.	0.6	196

#	ARTICLE	IF	CITATIONS
37	Outcome of Allogeneic Hematopoietic Stem-Cell Transplantation in Adult Patients With Acute Lymphoblastic Leukemia: No Difference in Related Compared With Unrelated Transplant in First Complete Remission. <i>Journal of Clinical Oncology</i> , 2004, 22, 2816-2825.	0.8	193
38	Aberrant splicing of U12-type introns is the hallmark of ZRSR2 mutant myelodysplastic syndrome. <i>Nature Communications</i> , 2015, 6, 6042.	5.8	192
39	Bone marrow cells are a rich source of growth factors and cytokines: implications for cell therapy trials after myocardial infarction. <i>European Heart Journal</i> , 2008, 29, 2851-2858.	1.0	191
40	IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis. <i>Haematologica</i> , 2010, 95, 1668-1674.	1.7	177
41	Lentivirus-mediated antagomir expression for specific inhibition of miRNA function. <i>Nucleic Acids Research</i> , 2007, 35, e149-e149.	6.5	171
42	Myeloid-derived growth factor (C19orf10) mediates cardiac repair following myocardial infarction. <i>Nature Medicine</i> , 2015, 21, 140-149.	15.2	168
43	TREATMENT OF ADULT ALL ACCORDING TO PROTOCOLS OF THE GERMAN MULTICENTER STUDY GROUP FOR ADULT ALL (GMALL). <i>Hematology/Oncology Clinics of North America</i> , 2000, 14, 1307-1325.	0.9	167
44	Mutations in the cohesin complex in acute myeloid leukemia: clinical and prognostic implications. <i>Blood</i> , 2014, 123, 914-920.	0.6	167
45	Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group. <i>Blood</i> , 2009, 113, 4505-4511.	0.6	164
46	Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study. <i>Leukemia Research</i> , 2010, 34, 1143-1150.	0.4	164
47	Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG). <i>Blood</i> , 2013, 121, 170-177.	0.6	164
48	Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG). <i>Blood</i> , 2013, 121, 4769-4777.	0.6	162
49	TIF1 $\hat{1}$ ³ , a novel member of the transcriptional intermediary factor 1 family. <i>Oncogene</i> , 1999, 18, 1209-1217.	2.6	157
50	Proteomic patterns predict acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. <i>Blood</i> , 2007, 109, 5511-5519.	0.6	157
51	Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions. <i>Oncotarget</i> , 2017, 8, 73483-73500.	0.8	153
52	The Human C3a Receptor Is Expressed on Neutrophils and Monocytes, but Not on B or T Lymphocytes. <i>Journal of Experimental Medicine</i> , 1997, 186, 199-207.	4.2	151
53	Proteins induced by telomere dysfunction and DNA damage represent biomarkers of human aging and disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 11299-11304.	3.3	151
54	Prothrombotic immune thrombocytopenia after COVID-19 vaccination. <i>Blood</i> , 2021, 138, 350-353.	0.6	145

#	ARTICLE	IF	CITATIONS
55	Monosomal karyotype in adult acute myeloid leukemia: prognostic impact and outcome after different treatment strategies. <i>Blood</i> , 2012, 119, 551-558.	0.6	140
56	Matched Unrelated or Matched Sibling Donors Result in Comparable Survival After Allogeneic Stem-Cell Transplantation in Elderly Patients With Acute Myeloid Leukemia: A Report From the Cooperative German Transplant Study Group. <i>Journal of Clinical Oncology</i> , 2008, 26, 5183-5191.	0.8	139
57	Treatment of Relapsed Acute Myeloid Leukemia. <i>Current Treatment Options in Oncology</i> , 2020, 21, 66.	1.3	138
58	Alloantigen-specific <i>de novo</i> induced Foxp3 ⁺ Treg revert <i>in vivo</i> and do not protect from experimental GVHD. <i>European Journal of Immunology</i> , 2009, 39, 3091-3096.	1.6	127
59	Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia. <i>Blood</i> , 2020, 135, 371-380.	0.6	127
60	Prognostic Impact of Minimal Residual Disease in <i>CBFB-MYH11</i> Positive Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2010, 28, 3724-3729.	0.8	126
61	Prognostic Value of Minimal Residual Disease Quantification by Real-Time Reverse Transcriptase Polymerase Chain Reaction in Patients With Core Binding Factor Leukemias. <i>Journal of Clinical Oncology</i> , 2003, 21, 4413-4422.	0.8	120
62	Circulating endothelial cells as a marker of endothelial damage in allogeneic hematopoietic stem cell transplantation. <i>Blood</i> , 2004, 103, 3603-3605.	0.6	115
63	Enhanced sensitivity to inhibition of SHP2, STAT5, and Gab2 expression in chronic myeloid leukemia (CML). <i>Blood</i> , 2006, 107, 3279-3287.	0.6	114
64	Next-generation sequencing for minimal residual disease monitoring in acute myeloid leukemia patients with <i>FLT3</i> -ITD or <i>NPM1</i> mutations. <i>Genes Chromosomes and Cancer</i> , 2012, 51, 689-695.	1.5	114
65	IFN- γ Production by Allogeneic Foxp3 ⁺ Regulatory T Cells Is Essential for Preventing Experimental Graft-versus-Host Disease. <i>Journal of Immunology</i> , 2012, 189, 2890-2896.	0.4	110
66	Posttransplant cyclophosphamide vs antithymocyte globulin in HLA-mismatched unrelated donor transplantation. <i>Blood</i> , 2019, 134, 892-899.	0.6	110
67	Reappearance of effector T cells is associated with recovery from COVID-19. <i>EBioMedicine</i> , 2020, 57, 102885.	2.7	109
68	The Multi-Kinase Inhibitor Midostaurin (M) Prolongs Survival Compared with Placebo (P) in Combination with Daunorubicin (D)/Cytarabine (C) Induction (ind), High-Dose C Consolidation (consol), and As Maintenance (maint) Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients (pts) Age 18-60 with FLT3 Mutations (mut): An International Prospective Randomized (rand) P-Controlled Double-Blind Trial (CALGB 10603/RATIFY [Alliance]). <i>Blood</i> , 2015, 126, 6-6.	0.6	104
69	Integrative prognostic risk score in acute myeloid leukemia with normal karyotype. <i>Blood</i> , 2011, 117, 4561-4568.	0.6	99
70	Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients. <i>Bone Marrow Transplantation</i> , 2020, 55, 1114-1125.	1.3	97
71	Improving acute promyelocytic leukemia (APL) outcome in developing countries through networking, results of the International Consortium on APL. <i>Blood</i> , 2013, 121, 1935-1943.	0.6	96
72	Genomic landscape and clonal evolution of acute myeloid leukemia with t(8;21): an international study on 331 patients. <i>Blood</i> , 2019, 133, 1140-1151.	0.6	96

#	ARTICLE	IF	CITATIONS
73	Autoimmunity Resulting From Cytokine Treatment Predicts Long-Term Survival in Patients With Metastatic Renal Cell Cancer. <i>Journal of Clinical Oncology</i> , 1999, 17, 529-529.	0.8	93
74	First Global Consensus for Evidence-Based Management of the Hematopoietic Syndrome Resulting From Exposure to Ionizing Radiation. <i>Disaster Medicine and Public Health Preparedness</i> , 2011, 5, 202-212.	0.7	91
75	Clonal evolution of acute myeloid leukemia with <i>FLT3</i> -ITD mutation under treatment with midostaurin. <i>Blood</i> , 2021, 137, 3093-3104.	0.6	91
76	Intracoronary autologous bone marrow cell transfer after myocardial infarction: the BOOST-2 randomised placebo-controlled clinical trial. <i>European Heart Journal</i> , 2017, 38, 2936-2943.	1.0	91
77	A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating <i>FLT3</i> mutations. <i>British Journal of Haematology</i> , 2015, 169, 694-700.	1.2	90
78	Impact of Molecular Genetics on Outcome in Myelofibrosis Patients after Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1095-1101.	2.0	89
79	Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation. <i>Nature Communications</i> , 2019, 10, 2031.	5.8	87
80	ASXL1 mutations in younger adult patients with acute myeloid leukemia: a study by the German-Austrian Acute Myeloid Leukemia Study Group. <i>Haematologica</i> , 2015, 100, 324-330.	1.7	86
81	Enforced expression of miR-125b affects myelopoiesis by targeting multiple signaling pathways. <i>Blood</i> , 2011, 117, 4338-4348.	0.6	85
82	Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group. <i>Blood</i> , 2019, 134, 1608-1618.	0.6	85
83	Decitabine improves progression-free survival in older high-risk MDS patients with multiple autosomal monosomies: results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group. <i>Annals of Hematology</i> , 2016, 95, 191-199.	0.8	84
84	Outcome after relapse of myelodysplastic syndrome and secondary acute myeloid leukemia following allogeneic stem cell transplantation: a retrospective registry analysis on 698 patients by the Chronic Malignancies Working Party of the European Society of Blood and Marrow Transplantation. <i>Haematologica</i> , 2018, 103, 237-245.	1.7	82
85	Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia—results of the AMLSG 11-08 trial. <i>Leukemia</i> , 2018, 32, 1621-1630.	3.3	81
86	Achievement of complete remission predicts outcome of allogeneic haematopoietic stem cell transplantation in patients with chronic myelomonocytic leukaemia. A study of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation. <i>British Journal of Haematology</i> , 2015, 171, 239-246.	1.2	80
87	Modulation of Gene Expression by Lentiviral-Mediated Delivery of Small Interfering RNA. <i>Cell Cycle</i> , 2003, 2, 250-256.	1.3	78
88	Literature Review and Global Consensus on Management of Acute Radiation Syndrome Affecting Nonhematopoietic Organ Systems. <i>Disaster Medicine and Public Health Preparedness</i> , 2011, 5, 183-201.	0.7	78
89	Cell of Origin in AML: Susceptibility to MN1-Induced Transformation Is Regulated by the MEIS1/AbdB-like HOX Protein Complex. <i>Cancer Cell</i> , 2011, 20, 39-52.	7.7	76
90	Stem cell transplantation in severe congenital neutropenia: an analysis from the European Society for Blood and Marrow Transplantation. <i>Blood</i> , 2015, 126, 1885-1892.	0.6	76

#	ARTICLE	IF	CITATIONS
91	Gemtuzumab Ozogamicin in <i>NPM1</i> -Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 623-632.	0.8	73
92	Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with <i>NPM1</i> -mutated AML: results from the AMLSG 09-09 trial. <i>Blood</i> , 2020, 136, 3041-3050.	0.6	73
93	A TNF-Regulated Recombinatorial Macrophage Immune Receptor Implicated in Granuloma Formation in Tuberculosis. <i>PLoS Pathogens</i> , 2011, 7, e1002375.	2.1	72
94	Interactions among HCLS1, HAX1 and LEF-1 proteins are essential for G-CSF-triggered granulopoiesis. <i>Nature Medicine</i> , 2012, 18, 1550-1559.	15.2	70
95	Lentiviral gene transfer into peripheral blood-derived CD34+ NOD/SCID-repopulating cells. <i>Blood</i> , 2002, 99, 709-712.	0.6	69
96	Haploidentical versus unrelated allogeneic stem cell transplantation for relapsed/refractory acute myeloid leukemia: a report on 1578 patients from the Acute Leukemia Working Party of the EBMT. <i>Haematologica</i> , 2019, 104, 524-532.	1.7	68
97	Rare occurrence of DNMT3A mutations in myelodysplastic syndromes. <i>Haematologica</i> , 2011, 96, 1870-1873.	1.7	67
98	Impact of Pegfilgrastim on Hematological Reconstitution and Incidence of Neutropenic Fever after Consolidation Therapy with High-Dose Cytarabine in Acute Myeloid Leukemia: Comparative Analysis between AMLSG 07-04 and the German AML Intergroup Trial. <i>Blood</i> , 2006, 108, 2020-2020.	0.6	67
99	Gene-expression profiles and their association with drug resistance in adult acute myeloid leukemia. <i>Haematologica</i> , 2005, 90, 1484-92.	1.7	67
100	High-resolution genomic profiling of adult and pediatric core-binding factor acute myeloid leukemia reveals new recurrent genomic alterations. <i>Blood</i> , 2012, 119, e67-e75.	0.6	66
101	Clonal Hematopoiesis of Indeterminate Potential. <i>Deutsches Arzteblatt International</i> , 2016, 113, 317-22.	0.6	65
102	Impact of different post-remission strategies on quality of life in patients with acute myeloid leukemia. <i>Haematologica</i> , 2008, 93, 826-833.	1.7	64
103	Valproate and Retinoic Acid in Combination With Decitabine in Elderly Nonfit Patients With Acute Myeloid Leukemia: Results of a Multicenter, Randomized, 2 × 2, Phase II Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 257-270.	0.8	63
104	Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent lymphomas: Nine-year updated results from the StiL NHL1 study. <i>Journal of Clinical Oncology</i> , 2017, 35, 7501-7501.	0.8	62
105	Acute leukemias of ambiguous lineage in adults: molecular and clinical characterization. <i>Annals of Hematology</i> , 2013, 92, 747-758.	0.8	61
106	All-trans retinoic acid as adjunct to intensive treatment in younger adult patients with acute myeloid leukemia: results of the randomized AMLSG 07-04 study. <i>Annals of Hematology</i> , 2016, 95, 1931-1942.	0.8	61
107	Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Age >69 Years with Acute Myelogenous Leukemia: On Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1975-1983.	2.0	61
108	Lipid nanoparticle-mediated siRNA delivery for safe targeting of human CML in vivo. <i>Annals of Hematology</i> , 2019, 98, 1905-1918.	0.8	61

#	ARTICLE	IF	CITATIONS
109	Human regulatory T cells in allogeneic stem cell transplantation. <i>Blood</i> , 2011, 118, e82-e92.	0.6	60
110	Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutations. <i>Blood Advances</i> , 2021, 5, 2294-2304.	2.5	60
111	Real-time RT-PCR for the detection and quantification of AML1/MTG8 fusion transcripts in t(8;21)-positive AML patients. <i>British Journal of Haematology</i> , 1999, 107, 80-85.	1.2	58
112	Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia study. <i>Annals of Hematology</i> , 2014, 93, 2001-2010.	0.8	58
113	Comparative genomic hybridization in the investigation of myeloid leukemias. <i>Genes Chromosomes and Cancer</i> , 1995, 12, 193-200.	1.5	56
114	Detection of karyotypic aberrations in acute myeloblastic leukaemia: a prospective comparison between PCR/FISH and standard cytogenetics in 140 patients with de novo AML. <i>British Journal of Haematology</i> , 1998, 103, 72-78.	1.2	56
115	The Effect of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor on Neutropenia and Related Morbidity in Chronic Severe Neutropenia. <i>Annals of Internal Medicine</i> , 1989, 111, 887.	2.0	54
116	Prognostic Importance of Histone Methyltransferase MLL5 Expression in Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2011, 29, 682-689.	0.8	53
117	Chromothripsis is linked to TP53 alteration, cell cycle impairment, and dismal outcome in acute myeloid leukemia with complex karyotype. <i>Haematologica</i> , 2018, 103, e17-e20.	1.7	53
118	HLA-Identical Sibling Allogeneic Transplants versus Chemotherapy in Acute Myelogenous Leukemia with t(8;21) in First Complete Remission: Collaborative Study between the German AML Intergroup and CIBMTR. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 187-196.	2.0	51
119	High-affinity neurotrophin receptors and ligands promote leukemogenesis. <i>Blood</i> , 2009, 113, 2028-2037.	0.6	51
120	Genetic characterization of acquired aplastic anemia by targeted sequencing. <i>Haematologica</i> , 2014, 99, e165-e167.	1.7	51
121	Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial. <i>Leukemia</i> , 2021, 35, 2539-2551.	3.3	51
122	Isolation strategies of regulatory T cells for clinical trials: Phenotype, function, stability, and expansion capacity. <i>Experimental Hematology</i> , 2011, 39, 1152-1160.	0.2	50
123	Specific Hammerhead Ribozyme-mediated Cleavage of Mutant N-ras mRNA in Vitro and ex Vivo. <i>Journal of Biological Chemistry</i> , 1997, 272, 14304-14313.	1.6	49
124	Hematopoietic Growth Factors in the Treatment of Acquired Bone Marrow Failure States. <i>Seminars in Hematology</i> , 2007, 44, 138-147.	1.8	49
125	Legionnaires' disease in immunocompromised patients: a case report of <i>Legionella longbeachae</i> pneumonia and review of the literature. <i>Journal of Medical Microbiology</i> , 2008, 57, 384-387.	0.7	49
126	Mobilized Peripheral Blood Stem Cells Compared with Bone Marrow as the Stem Cell Source for Unrelated Donor Allogeneic Transplantation with Reduced-Intensity Conditioning in Patients with Acute Myeloid Leukemia in Complete Remission: An Analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1422-1429.	2.0	49

#	ARTICLE	IF	CITATIONS
127	Hematologic responses in patients with aplastic anemia treated with deferasirox: a post hoc analysis from the EPIC study. <i>Haematologica</i> , 2013, 98, 1045-1048.	1.7	49
128	Individual outcome prediction for myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia from MDS after allogeneic hematopoietic cell transplantation. <i>Annals of Hematology</i> , 2017, 96, 1361-1372.	0.8	49
129	Allogeneic Stem Cell Transplantation for Patients Age \geq 70 Years with Myelodysplastic Syndrome: A Retrospective Study of the MDS Subcommittee of the Chronic Malignancies Working Party of the EBMT. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 44-52.	2.0	49
130	Recovery and composition of microparticles after snap-freezing depends on thawing temperature. <i>Blood Coagulation and Fibrinolysis</i> , 2009, 20, 52-56.	0.5	48
131	Cytoreductive treatment with clofarabine/ara-C combined with reduced-intensity conditioning and allogeneic stem cell transplantation in patients with high-risk, relapsed, or refractory acute myeloid leukemia and advanced myelodysplastic syndrome. <i>European Journal of Haematology</i> , 2012, 88, 52-60.	1.1	48
132	Prognostic significance of expression levels of stem cell regulators MSI2 and NUMB in acute myeloid leukemia. <i>Annals of Hematology</i> , 2013, 92, 315-323.	0.8	48
133	Stem Cells, Multiorgan Failure in Radiation Emergency Medical Preparedness: A U.S./European Consultation Workshop. <i>Stem Cells</i> , 2009, 27, 1205-1211.	1.4	47
134	A Tagging-via-substrate Approach to Detect the Farnesylated Proteome Using Two-dimensional Electrophoresis Coupled with Western Blotting. <i>Molecular and Cellular Proteomics</i> , 2010, 9, 742-751.	2.5	47
135	Improved short- and long-term outcome of allogeneic stem cell recipients admitted to the intensive care unit: a retrospective longitudinal analysis of 942 patients. <i>Intensive Care Medicine</i> , 2018, 44, 1483-1492.	3.9	46
136	Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial. <i>Leukemia</i> , 2020, 34, 914-918.	3.3	46
137	FLT3-internal tandem duplication and age are the major prognostic factors in patients with relapsed acute myeloid leukemia with normal karyotype. <i>Haematologica</i> , 2011, 96, 681-686.	1.7	45
138	Genomic heterogeneity in core-binding factor acute myeloid leukemia and its clinical implication. <i>Blood Advances</i> , 2020, 4, 6342-6352.	2.5	45
139	Diagnostic value of procalcitonin serum levels in comparison with C-reactive protein in allogeneic stem cell transplantation. <i>Haematologica</i> , 2002, 87, 643-51.	1.7	45
140	Prognosis of acute myeloid leukemia patients up to 60 years of age exhibiting trisomy 8 within a non-complex karyotype: individual patient data-based meta-analysis of the German Acute Myeloid Leukemia Intergroup. <i>Haematologica</i> , 2007, 92, 763-770.	1.7	44
141	Acute but not chronic graft-versus-host disease is associated with a reduction of circulating CD4 ⁺ CD25 ^{high} CD127 ^{low} / α^{β} regulatory T cells. <i>Annals of Hematology</i> , 2011, 90, 213-218.	0.8	44
142	Dendritic Cell-Mediated Immune Humanization of Mice: Implications for Allogeneic and Xenogeneic Stem Cell Transplantation. <i>Journal of Immunology</i> , 2014, 192, 4636-4647.	0.4	44
143	Transplant Outcomes for Secondary Acute Myeloid Leukemia: Acute Leukemia Working Party of the European Society for Blood and Bone Marrow Transplantation Study. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1406-1414.	2.0	44
144	BLAST: A Confirmatory, Single-Arm, Phase 2 Study of Blinatumomab, a Bispecific T-Cell Engager (BiTE [®]) Antibody Construct, in Patients with Minimal Residual Disease B-Precursor Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2014, 124, 379-379.	0.6	44

#	ARTICLE	IF	CITATIONS
145	Incidence of lineage promiscuity in acute myeloblastic leukemia: Diagnostic implications of immunoglobulin and T-cell receptor gene rearrangement analysis and immunological phenotyping. <i>Leukemia Research</i> , 1988, 12, 887-895.	0.4	42
146	Correction of Respiratory Burst Activity in X-Linked Chronic Granulomatous Cells to Therapeutically Relevant Levels after Gene Transfer into Bone Marrow CD34+Cells. <i>Human Gene Therapy</i> , 1998, 9, 1561-1570.	1.4	42
147	Combining prenylation inhibitors causes synergistic cytotoxicity, apoptosis and disruption of RAS-to-MAP kinase signalling in multiple myeloma cells. <i>British Journal of Haematology</i> , 2005, 130, 912-925.	1.2	42
148	Peripheral blood stem cell graft compared to bone marrow after reduced intensity conditioning regimens for acute leukemia: a report from the ALWP of the EBMT. <i>Haematologica</i> , 2016, 101, 256-262.	1.7	42
149	Haploidentical transplantation and posttransplant cyclophosphamide for treating aplastic anemia patients: a report from the EBMT Severe Aplastic Anemia Working Party. <i>Bone Marrow Transplantation</i> , 2020, 55, 1050-1058.	1.3	42
150	Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results. <i>Leukemia</i> , 2022, 36, 90-99.	3.3	42
151	Quantification and Facilitated Comparison of von Willebrand Factor Multimer Patterns by Densitometry. <i>American Journal of Clinical Pathology</i> , 2001, 116, 567-574.	0.4	41
152	Evidence for allelic evolution of C/EBPalpha mutations in acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2003, 123, 413-419.	1.2	40
153	Cutaneous Side Effects of New Antitumor Drugs. <i>Deutsches A&#x0308;rztblatt International</i> , 2012, 109, 133-40.	0.6	40
154	Distinct splicing signatures affect converged pathways in myelodysplastic syndrome patients carrying mutations in different splicing regulators. <i>Rna</i> , 2016, 22, 1535-1549.	1.6	40
155	Inferior outcome of allogeneic stem cell transplantation for secondary acute myeloid leukemia in first complete remission as compared to de novo acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2020, 10, 26.	2.8	40
156	ILâ€³ in the Clinic. <i>Stem Cells</i> , 1997, 15, 327-333.	1.4	39
157	Detection of Antisense and Ribozyme Accessible Sites on Native mRNAs: Application to NCOA3 mRNA. <i>Molecular Therapy</i> , 2001, 4, 454-460.	3.7	39
158	Evolution of FLT3-ITD and D835 activating point mutations in relapsing acute myeloid leukemia and response to salvage therapy. <i>Leukemia Research</i> , 2004, 28, 1069-1074.	0.4	39
159	Online coupling of capillary electrophoresis with mass spectrometry for the identification of biomarkers for clinical diagnosis. <i>Expert Review of Proteomics</i> , 2005, 2, 639-647.	1.3	39
160	Azacitidine for treatment of patients with myelodysplastic syndromes (MDS): practical recommendations of the German MDS Study Group. <i>Annals of Hematology</i> , 2010, 89, 841-850.	0.8	39
161	The neutrophil recombinatorial TCR-like immune receptor is expressed across the entire human life span but repertoire diversity declines in old age. <i>Biochemical and Biophysical Research Communications</i> , 2012, 419, 309-315.	1.0	39
162	High-dose therapy and autologous stem cell transplantation for extra-nodal NK/T lymphoma in patients from the Western hemisphere: a study from the European Society for Blood and Marrow Transplantation. <i>Leukemia and Lymphoma</i> , 2015, 56, 3295-3300.	0.6	39

#	ARTICLE	IF	CITATIONS
163	Comparing transplant outcomes in ALL patients after haploidentical with PTCy or matched unrelated donor transplantation. <i>Blood Advances</i> , 2020, 4, 2073-2083.	2.5	39
164	Comparison of matched sibling donors versus unrelated donors in allogeneic stem cell transplantation for primary refractory acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT. <i>Journal of Hematology and Oncology</i> , 2017, 10, 130.	6.9	38
165	Sequential Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Intermediate- or High-Risk Acute Myeloid Leukemia in Complete Remission: A Study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 278-284.	2.0	38
166	CAR-T Cells Targeting Epstein-Barr Virus gp350 Validated in a Humanized Mouse Model of EBV Infection and Lymphoproliferative Disease. <i>Molecular Therapy - Oncolytics</i> , 2020, 18, 504-524.	2.0	38
167	Prognostic significance of combined MN1, ERG, BAALC, and EVI1 (MEBE) expression in patients with myelodysplastic syndromes. <i>Annals of Hematology</i> , 2012, 91, 1221-1233.	0.8	37
168	Elevated frequencies of leukemic myeloid and plasmacytoid dendritic cells in acute myeloid leukemia with the FLT3 internal tandem duplication. <i>Annals of Hematology</i> , 2011, 90, 1047-1058.	0.8	36
169	Detection and quantification of CBFB/MYH11 fusion transcripts in patients with inv(16)-positive acute myeloblastic leukemia by real-time RT-PCR. <i>Genes Chromosomes and Cancer</i> , 2001, 30, 342-348.	1.5	35
170	Morphology and quantitative composition of hematopoietic cells in murine bone marrow and spleen of healthy subjects. <i>Annals of Hematology</i> , 2013, 92, 587-594.	0.8	35
171	Unrelated donor versus matched sibling donor in adults with acute myeloid leukemia in first relapse: an ALWP-EBMT study. <i>Journal of Hematology and Oncology</i> , 2016, 9, 89.	6.9	35
172	<i>Candida kefyr</i> as an Emerging Pathogen Causing Nosocomial Bloodstream Infections in Neutropenic Leukemia Patients. <i>Clinical Infectious Diseases</i> , 2005, 41, 1365-1366.	2.9	34
173	Diagnostic value of highly-sensitive chimerism analysis after allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 1457-1465.	1.3	34
174	Conditioning intensity in secondary AML with prior myelodysplastic syndrome/myeloproliferative disorders: an EBMT ALWP study. <i>Blood Advances</i> , 2018, 2, 2127-2135.	2.5	34
175	Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial. <i>Blood Advances</i> , 2020, 4, 4945-4954.	2.5	34
176	Clinical and prognostic role of plasma coagulation factor XIII activity for bleeding disorders and 6-year survival in patients with chronic liver disease. <i>Liver International</i> , 2006, 26, 173-181.	1.9	33
177	Monitoring dendritic cell and cytokine biomarkers during remission prior to relapse in patients with FLT3-ITD acute myeloid leukemia. <i>Annals of Hematology</i> , 2013, 92, 1079-1090.	0.8	33
178	Induction of TNF- α in patients with myelodysplastic syndromes undergoing treatment with interleukin-3. <i>British Journal of Haematology</i> , 1993, 84, 749-751.	1.2	32
179	Use of Colony-Stimulating Factors for Chemotherapy-Associated Neutropenia: Review of Current Guidelines. <i>Seminars in Hematology</i> , 2007, 44, 148-156.	1.8	32
180	Isotype controls in phenotyping and quantification of microparticles: A major source of error and how to evade it. <i>Thrombosis Research</i> , 2008, 122, 691-700.	0.8	32

#	ARTICLE	IF	CITATIONS
181	Outcomes in <sc>RBC</sc> transfusionâ€dependent patients with <sc>L</sc>owâ€<sc>I</sc>ntermediateâ€1â€risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the <sc>MDS</sc>â€004 study. <i>European Journal of Haematology</i> , 2014, 93, 429-438.	1.1	32
182	Midostaurin in Combination with Intensive Induction and As Single Agent Maintenance Therapy after Consolidation Therapy with Allogeneic Hematopoietic Stem Cell Transplantation or High-Dose Cytarabine (NCT01477606). <i>Blood</i> , 2015, 126, 322-322.	0.6	32
183	Influence of molecular subgroups on outcome of acute myeloid leukemia with normal karyotype in 141 patients undergoing salvage allogeneic stem cell transplantation in primary induction failure or beyond first relapse. <i>Haematologica</i> , 2013, 98, 518-525.	1.7	31
184	All-trans retinoic acid with daunorubicin or idarubicin for risk-adapted treatment of acute promyelocytic leukaemia: a matched-pair analysis of the PETHEMA LPA-2005 and IC-APL studies. <i>Annals of Hematology</i> , 2015, 94, 1347-1356.	0.8	31
185	T cell receptor Î³ chain variable gene rearrangements in acute lymphoblastic leukemias of T and B lineage. <i>European Journal of Immunology</i> , 1987, 17, 1593-1597.	1.6	30
186	Colony-stimulating factors in the management of neutropenia and its complications. <i>Annals of Hematology</i> , 2005, 84, 697-708.	0.8	30
187	Therapy-related myeloid neoplasms. <i>Current Opinion in Hematology</i> , 2017, 24, 152-158.	1.2	30
188	Outcome of patients with Fanconi anemia developing myelodysplasia and acute leukemia who received allogeneic hematopoietic stem cell transplantation: A retrospective analysis on behalf of <sc>EBMT</sc> group. <i>American Journal of Hematology</i> , 2020, 95, 809-816.	2.0	30
189	IDH1/2 mutations in acute myeloid leukemia patients and risk of coronary artery disease and cardiac dysfunctionâ€a retrospective propensity score analysis. <i>Leukemia</i> , 2021, 35, 1301-1316.	3.3	30
190	Fluorescence in Situ Hybridization (FISH) Is a Reliable Diagnostic Tool for Detection of the 9; 22 Translocation. <i>Leukemia and Lymphoma</i> , 1996, 22, 287-294.	0.6	29
191	Sequential Anti-Cytomegalovirus Response Monitoring May Allow Prediction of Cytomegalovirus Reactivation after Allogeneic Stem Cell Transplantation. <i>PLoS ONE</i> , 2012, 7, e50248.	1.1	29
192	BCR-ABL Affects STAT5A and STAT5B Differentially. <i>PLoS ONE</i> , 2014, 9, e97243.	1.1	29
193	Synergistic activity of IDH1 inhibitor BAY1436032 with azacitidine in IDH1 mutant acute myeloid leukemia. <i>Haematologica</i> , 2021, 106, 565-573.	1.7	29
194	Targeted Inhibition of the NUP98-NSD1 Fusion Oncogene in Acute Myeloid Leukemia. <i>Cancers</i> , 2020, 12, 2766.	1.7	29
195	High Î³Np73/TAp73 ratio is associated with poor prognosis in acute promyelocytic leukemia. <i>Blood</i> , 2015, 126, 2302-2306.	0.6	28
196	Radioimmunotherapy with [188Re]-labelled anti-CD66 antibody in the conditioning for allogeneic stem cell transplantation for high-risk acute myeloid leukemia. <i>International Journal of Hematology</i> , 2008, 87, 414-421.	0.7	27
197	Surveillance with successful reduction of central line-associated bloodstream infections among neutropenic patients with hematologic or oncologic malignancies. <i>Annals of Hematology</i> , 2009, 88, 907-912.	0.8	27
198	<i>TET2</i> mutations in cytogenetically normal acute myeloid leukemia: Clinical implications and evolutionary patterns. <i>Genes Chromosomes and Cancer</i> , 2014, 53, 824-832.	1.5	27

#	ARTICLE	IF	CITATIONS
199	FLAVIDA salvage chemotherapy combined with a seven-day course of venetoclax (FLAVIDA) in patients with relapsed/refractory acute leukaemia. <i>British Journal of Haematology</i> , 2020, 188, e11-e15.	1.2	27
200	MYELODYSPLASTIC SYNDROME AND ACUTE MYELOGENOUS LEUKEMIA SECONDARY TO HEART TRANSPLANTATION. <i>Transplantation</i> , 2000, 70, 688-690.	0.5	26
201	Treatment of myelodysplastic syndrome with isolated del(5q) including bands q31-q33 with a combination of all-trans-retinoic acid and tocopherol- β : a phase II study. <i>Annals of Hematology</i> , 2005, 84, 389-394.	0.8	26
202	Clofarabine-containing conditioning regimen for allo-SCT in <sc>AML</sc>/<sc>ALL</sc> patients: a survey from the Acute Leukemia Working Party of <sc>EBMT</sc>. <i>European Journal of Haematology</i> , 2012, 89, 214-219.	1.1	26
203	Impact of MLL5 expression on decitabine efficacy and DNA methylation in acute myeloid leukemia. <i>Haematologica</i> , 2014, 99, 1456-1464.	1.7	26
204	Sequential chemotherapy followed by reduced-intensity conditioning and allogeneic haematopoietic stem cell transplantation in adult patients with relapse or refractory acute myeloid leukaemia: a survey from the Acute Leukaemia Working Party of <sc>EBMT</sc>. <i>British Journal of Haematology</i> , 2017, 176, 431-439.	1.2	26
205	Thrombopoietin serum levels are elevated in patients with hepatitis B/C infection compared to other causes of chronic liver disease. <i>Liver</i> , 2002, 22, 114-120.	0.1	25
206	Acquired haemophilia caused by non-haemophilic factor VIII gene variants. <i>Annals of Hematology</i> , 2010, 89, 607-612.	0.8	25
207	Genetically Modified Donor Leukocyte Transfusion and Graft-Versus-Leukemia Effect After Allogeneic Stem Cell Transplantation. <i>Human Gene Therapy</i> , 2011, 22, 829-841.	1.4	25
208	Syngeneic transplantation in aplastic anemia: pre-transplant conditioning and peripheral blood are associated with improved engraftment: an observational study on behalf of the Severe Aplastic Anemia and Pediatric Diseases Working Parties of the European Group for Blood and Marrow Transplantation. <i>Haematologica</i> , 2013, 98, 1804-1809.	1.7	25
209	Role of Age and Hematopoietic Cell Transplantation-Specific Comorbidity Index in Myelodysplastic Patients Undergoing an Allotransplant: A Retrospective Study from the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 451-457.	2.0	25
210	Extracorporeal cytokine removal in severe CAR-T cell associated cytokine release syndrome. <i>Journal of Critical Care</i> , 2020, 57, 124-129.	1.0	25
211	Human Regulatory T Cells of G-CSF Mobilized Allogeneic Stem Cell Donors Qualify for Clinical Application. <i>PLoS ONE</i> , 2012, 7, e51644.	1.1	24
212	Lentivirus-Induced Dendritic Cells for Immunization Against High-Risk WT1 ⁺ Acute Myeloid Leukemia. <i>Human Gene Therapy</i> , 2013, 24, 220-237.	1.4	24
213	Impaired Functionality of Antiviral T Cells in G-CSF Mobilized Stem Cell Donors: Implications for the Selection of CTL Donor. <i>PLoS ONE</i> , 2013, 8, e77925.	1.1	24
214	Late treatment-related mortality versus competing causes of death after allogeneic transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia. <i>Leukemia</i> , 2019, 33, 686-695.	3.3	24
215	Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results from the 18 F-Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL) trial. <i>Annals of Hematology</i> , 2019, 98, 897-907.	0.8	24
216	Midostaurin plus intensive chemotherapy for younger and older patients with AML and <i>FLT3</i> internal tandem duplications. <i>Blood Advances</i> , 2022, 6, 5345-5355.	2.5	24

#	ARTICLE	IF	CITATIONS
217	Synthesis and properties of hammerhead ribozymes stabilized against nucleases by different 2'-modifications: methoxyethoxy-, fluoro- and amino groups. <i>Bioorganic and Medicinal Chemistry Letters</i> , 1997, 7, 1791-1796.	1.0	23
218	Differential Quantitation of Alternatively Spliced Messenger RNAs Using Isoform-Specific Real-Time RT-PCR. <i>Analytical Biochemistry</i> , 1999, 269, 210-213.	1.1	23
219	Inflammatory pseudotumor of the lung following invasive aspergillosis in a patient with chronic graft-vs.-host disease. <i>European Journal of Haematology</i> , 2005, 75, 68-72.	1.1	23
220	Effects of pharmacological intervention on coagulopathy and organ function in xenoperfused kidneys. <i>Xenotransplantation</i> , 2008, 15, 46-55.	1.6	23
221	A one-mutation mathematical model can explain the age incidence of acute myeloid leukemia with mutated nucleophosmin (NPM1). <i>Haematologica</i> , 2008, 93, 1219-1226.	1.7	23
222	<i>In vitro</i> improvement of bone marrow-derived hematopoietic colony formation in HIV-positive patients by alpha-D-tocopherol and erythropoietin. <i>European Journal of Haematology</i> , 1994, 53, 201-206.	1.1	23
223	Human Effector Memory T Helper Cells Engage with Mouse Macrophages and Cause Graft-versus-Host-Like Pathology in Skin of Humanized Mice Used in a Nonclinical Immunization Study. <i>American Journal of Pathology</i> , 2017, 187, 1380-1398.	1.9	23
224	Signatures of T and B Cell Development, Functional Responses and PD-1 Upregulation After HCMV Latent Infections and Reactivations in Nod.Rag.Gamma Mice Humanized With Cord Blood CD34+ Cells. <i>Frontiers in Immunology</i> , 2018, 9, 2734.	2.2	23
225	Cytogenetic Studies in Chronic Myeloproliferative Disorders. <i>Acta Haematologica</i> , 1983, 69, 145-151.	0.7	22
226	Bone Marrow Findings after Treatment with Recombinant Human Interleukin-3. <i>American Journal of Clinical Pathology</i> , 1991, 95, 355-362.	0.4	22
227	ITD- and FL-induced FLT3 signal transduction leads to increased C/EBP β -LIP expression and LIP/LAP ratio by different signalling modules. <i>British Journal of Haematology</i> , 2010, 148, 777-790.	1.2	22
228	Engineered dendritic cells from cord blood and adult blood accelerate effector T cell immune reconstitution against HCMV. <i>Molecular Therapy - Methods and Clinical Development</i> , 2015, 2, 14060.	1.8	22
229	Salvage therapy with high-dose cytarabine and mitoxantrone in combination with all-trans retinoic acid and gemtuzumab ozogamicin in acute myeloid leukemia refractory to first induction therapy. <i>Haematologica</i> , 2016, 101, 839-845.	1.7	22
230	Characterization of High-Avidity Cytomegalovirus-Specific T Cells with Differential Tetramer Binding Coappearing after Allogeneic Stem Cell Transplantation. <i>Journal of Immunology</i> , 2017, 199, 792-805.	0.4	22
231	Improved Outcome in High Risk and Very High Risk ALL by Risk Adapted SCT and in Standard Risk ALL by Intensive Chemotherapy in 713 Adult ALL Patients Treated According to the Prospective GMALL Study 07/2003.. <i>Blood</i> , 2007, 110, 12-12.	0.6	22
232	Novel Therapies in Advanced Renal Cell Carcinoma. <i>Deutsches A&#x0308;rztblatt International</i> , 2008, 105, 232-7.	0.6	22
233	Possible Impact of Cytomegalovirus-Specific CD8 + T Cells on Immune Reconstitution and Conversion to Complete Donor Chimerism after Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1046-1053.	2.0	21
234	Combining gene mutation with gene expression analysis improves outcome prediction in acute promyelocytic leukemia. <i>Blood</i> , 2019, 134, 951-959.	0.6	21

#	ARTICLE	IF	CITATIONS
235	Clinical and functional implications of microRNA mutations in a cohort of 935 patients with myelodysplastic syndromes and acute myeloid leukemia. <i>Haematologica</i> , 2015, 100, e122-e124.	1.7	20
236	Decitabine versus best supportive care in older patients with refractory anemia with excess blasts in transformation (RAEBt) - results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group (GMDSSG). <i>Annals of Hematology</i> , 2015, 94, 2003-2013.	0.8	20
237	Optimized induction of mitochondrial apoptosis for chemotherapy-free treatment of BCR-ABL+acute lymphoblastic leukemia. <i>Leukemia</i> , 2019, 33, 1313-1323.	3.3	20
238	Paroxysmal nocturnal hemoglobinuria Differential gene expression of EGR-1 and TAXREB107. <i>Experimental Hematology</i> , 2002, 30, 18-25.	0.2	19
239	Recombinant human erythropoietin in the treatment of nonrenal anemia. <i>Annals of Hematology</i> , 2006, 85, 69-78.	0.8	19
240	Comparison of FLAMSA-based reduced intensity conditioning with treosulfan/fludarabine conditioning for patients with acute myeloid leukemia: an ALWP/EBMT analysis. <i>Bone Marrow Transplantation</i> , 2019, 54, 531-539.	1.3	19
241	Clinical use of hematopoietic growth factors. <i>Current Opinion in Oncology</i> , 1996, 8, 265-269.	1.1	18
242	Plasma P-selectin levels are elevated in patients with chronic liver disease. <i>Blood Coagulation and Fibrinolysis</i> , 2003, 14, 319-325.	0.5	18
243	Value of proteomics applied to the follow-up in stem cell transplantation. <i>Annals of Hematology</i> , 2006, 85, 205-211.	0.8	18
244	Carboplatin plus weekly docetaxel as salvage chemotherapy in docetaxel-resistant and castration-resistant prostate cancer. <i>World Journal of Urology</i> , 2010, 28, 391-398.	1.2	18
245	Umbilical cord blood versus unrelated donor transplantation in adults with primary refractory or relapsed acute myeloid leukemia: a report from Eurocord, the Acute Leukemia Working Party and the Cord Blood Committee of the Cellular Therapy and Immunobiology Working Party of the EBMT. <i>Blood Cancer Journal</i> , 2019, 9, 46.	2.8	18
246	Baseline and interim PET-based outcome prediction in peripheral T-cell lymphoma: A subgroup analysis of the PETAL trial. <i>Hematological Oncology</i> , 2020, 38, 244-256.	0.8	18
247	All-Trans Retinoic Acid Improves Outcome in Younger Adult Patients with Nucleophosmin-1 Mutated Acute Myeloid Leukemia – Results of the AMLSG 07-04 Randomized Treatment Trial. <i>Blood</i> , 2011, 118, 80-80.	0.6	18
248	ATRA and Arsenic Trioxide (ATO) Versus ATRA and Idarubicin (AIDA) for Newly Diagnosed, Non High-Risk Acute Promyelocytic Leukemia (APL): Results of the Phase III, Prospective, Randomized, Intergroup APL0406 Study by the Italian-German Cooperative Groups Gimema-SAL-AMLSG. <i>Blood</i> , 2012, 120, 6-6.	0.6	18
249	Impact of Age and Midostaurin-Dose on Response and Outcome in Acute Myeloid Leukemia with FLT3-ITD: Interim-Analyses of the AMLSG 16-10 Trial. <i>Blood</i> , 2016, 128, 449-449.	0.6	18
250	Shedding of the endothelial receptor tyrosine kinase Tie2 correlates with leukemic blast burden and outcome after allogeneic hematopoietic stem cell transplantation for AML. <i>Annals of Hematology</i> , 2010, 89, 459-467.	0.8	17
251	Long term follow up of patients after allogeneic stem cell transplantation and transfusion of HSV-TK transduced T-cells. <i>Frontiers in Pharmacology</i> , 2015, 6, 76.	1.6	17
252	Pyrimethamine as a Potent and Selective Inhibitor of Acute Myeloid Leukemia Identified by High-throughput Drug Screening. <i>Current Cancer Drug Targets</i> , 2016, 16, 818-828.	0.8	17

#	ARTICLE	IF	CITATIONS
253	The impact of HLA-matching on reduced intensity conditioning regimen unrelated donor allogeneic stem cell transplantation for acute myeloid leukemia in patients above 50 years—a report from the EBMT acute leukemia working party. <i>Journal of Hematology and Oncology</i> , 2016, 9, 65.	6.9	17
254	FLAMSA-Based Reduced-Intensity Conditioning versus Myeloablative Conditioning in Younger Patients with Relapsed/Refractory Acute Myeloid Leukemia with Active Disease at the Time of Allogeneic Stem Cell Transplantation: An Analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2165-2173.	2.0	17
255	¹⁸ F-FDG PET/CT of off-target lymphoid organs in CD19-targeting chimeric antigen receptor T-cell therapy for relapsed or refractory diffuse large B-cell lymphoma. <i>Annals of Nuclear Medicine</i> , 2021, 35, 132-138.	1.2	17
256	Second allogeneic haematopoietic cell transplantation using HLA-matched unrelated versus T-cell replete haploidentical donor and survival in relapsed acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2021, 193, 592-601.	1.2	17
257	Role of Consolidation Therapy in the Treatment of Patients up to 60 Years with High Risk AML. <i>Blood</i> , 2005, 106, 172-172.	0.6	17
258	Two years rituximab maintenance vs. observation after first line treatment with bendamustine plus rituximab (B-R) in patients with marginal zone lymphoma (MZL): Results of a prospective, randomized, multicenter phase 2 study (the StiL NHL7-2008 MAINTAIN trial). <i>Journal of Clinical Oncology</i> , 2018, 36, 7515-7515.	0.8	17
259	Generation of lentivirus-induced dendritic cells under GMP-compliant conditions for adaptive immune reconstitution against cytomegalovirus after stem cell transplantation. <i>Journal of Translational Medicine</i> , 2015, 13, 240.	1.8	16
260	Successful use of extracorporeal membrane oxygenation during induction chemotherapy in a patient with mediastinal tumor mass of a T lymphoblastic lymphoma. <i>Annals of Hematology</i> , 2016, 95, 1719-1721.	0.8	16
261	Comparable Long-Term Outcome after Allogeneic Stem Cell Transplantation from Sibling and Matched Unrelated Donors in Patients with Acute Myeloid Leukemia Older Than 50 Years: A Report on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2251-2260.	2.0	16
262	Comparative outcomes of myeloablative and reduced-intensity conditioning allogeneic hematopoietic cell transplantation for therapy-related acute myeloid leukemia with prior solid tumor: A report from the acute leukemia working party of the European society for blood and bone marrow transplantation. <i>American Journal of Hematology</i> , 2019, 94, 431-438.	2.0	16
263	miR-181a Expression in Donor T Cells Modulates Graft-versus-Host Disease after Allogeneic Bone Marrow Transplantation. <i>Journal of Immunology</i> , 2016, 196, 3927-3934.	0.4	15
264	Monosomal karyotype and chromosome 17p loss or TP53 mutations in decitabine-treated patients with acute myeloid leukemia. <i>Annals of Hematology</i> , 2020, 99, 1551-1560.	0.8	15
265	Venetoclax and dexamethasone synergize with inotuzumab ozogamicin-induced DNA damage signaling in B-lineage ALL. <i>Blood</i> , 2021, 137, 2657-2661.	0.6	15
266	Continued Low-Dose Decitabine (DAC) Is an Active First-Line Treatment of Older AML Patients: First Results of a Multicenter Phase II Study. <i>Blood</i> , 2005, 106, 1852-1852.	0.6	15
267	Continued Low-Dose Decitabine (DAC) Is an Active First-Line Treatment in All Cytogenetic Subgroups of Older AML Patients: Results of the FR00331 Multicenter Phase II Study. <i>Blood</i> , 2007, 110, 300-300.	0.6	15
268	Megakaryocytic cells in mixed haemopoietic colonies (CFU-GEMM) from the peripheral blood of normal individuals. <i>British Journal of Haematology</i> , 1985, 59, 627-633.	1.2	14
269	Inhibition of granulocyte-macrophage colony-stimulating factor receptor function by a splice variant of the common β -receptor subunit. <i>Blood</i> , 2001, 98, 2689-2696.	0.6	14
270	Quantification of hepatic thrombopoietin mRNA transcripts in patients with chronic liver diseases shows maintained gene expression in different etiologies of liver cirrhosis. <i>Liver</i> , 2002, 22, 205-212.	0.1	14

#	ARTICLE	IF	CITATIONS
271	Sinusoidal Obstruction Syndrome of the Liver after Hematopoietic Stem Cell Transplantation: Decision Making for Orthotopic Liver Transplantation. <i>International Journal of Hematology</i> , 2006, 83, 271-274.	0.7	14
272	Risks and Benefits of Erythropoiesis-Stimulating Agents in Cancer Management. <i>Seminars in Hematology</i> , 2007, 44, 157-165.	1.8	14
273	Preconditioning Therapy with Lentiviral Vector-Programmed Dendritic Cells Accelerates the Homeostatic Expansion of Antigen-Reactive Human T Cells in NOD.Rag1 ^{-/-} .IL-2r ^{3c} mice. <i>Human Gene Therapy</i> , 2011, 22, 1209-1224.	1.4	14
274	Myeloid growth factors in acute myeloid leukemia: systematic review of randomized controlled trials. <i>Annals of Hematology</i> , 2011, 90, 273-281.	0.8	14
275	Modulation of anthracycline-induced cytotoxicity by targeting the prenylated proteome in myeloid leukemia cells. <i>Journal of Molecular Medicine</i> , 2012, 90, 149-161.	1.7	14
276	Leukemogenic potency of the novel FLT3-N676K mutant. <i>Annals of Hematology</i> , 2016, 95, 783-791.	0.8	14
277	A Phase II study of selinexor plus cytarabine and idarubicin in patients with relapsed/refractory acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2020, 190, e169-e173.	1.2	14
278	Measurable residual disease status and outcome of transplant in acute myeloid leukemia in second complete remission: a study by the acute leukemia working party of the EBMT. <i>Blood Cancer Journal</i> , 2021, 11, 88.	2.8	14
279	Monitoring of Minimal Residual Disease in NPM1 Mutated Acute Myeloid Leukemia (AML): Results of the AML Study Group (AMLSG). <i>Blood</i> , 2008, 112, 699-699.	0.6	14
280	The AML1/MTG8 Fusion Transcript in t(8;21) Positive AML and its Implication for the Detection of Minimal Residual Disease. <i>Hematology</i> , 2000, 5, 369-381.	0.7	13
281	Up-front randomization and common standard arm: a proposal for comparing AML treatment strategies between different studies. <i>Leukemia Research</i> , 2002, 26, 1073-1075.	0.4	13
282	Prognostic impact of KMT2E transcript levels on outcome of patients with acute promyelocytic leukaemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukaemia study. <i>British Journal of Haematology</i> , 2014, 166, 540-549.	1.2	13
283	Spatiotemporally Skewed Activation of Programmed Cell Death Receptor 1 Positive T Cells after Epstein-Barr Virus Infection and Tumor Development in Long-Term Fully Humanized Mice. <i>American Journal of Pathology</i> , 2019, 189, 521-539.	1.9	13
284	In vivo efficacy of mutant IDH1 inhibitor HMS-101 and structural resolution of distinct binding site. <i>Leukemia</i> , 2020, 34, 416-426.	3.3	13
285	Effective drug treatment identified by in vivo screening in a transplantable patient-derived xenograft model of chronic myelomonocytic leukemia. <i>Leukemia</i> , 2020, 34, 2951-2963.	3.3	13
286	Impact of sarcopenia in advanced and metastatic soft tissue sarcoma. <i>International Journal of Clinical Oncology</i> , 2021, 26, 2151-2160.	1.0	13
287	Impact of Allogeneic Transplantation From Matched Related and Unrelated Donors on Clinical Outcome In Younger Adult AML Patients with FLT3 Internal Tandem Duplications. <i>Blood</i> , 2010, 116, 909-909.	0.6	13
288	Use of hematopoietic growth factors in the treatment of acute myelogenous leukemia. <i>Current Opinion in Hematology</i> , 1997, 4, 191-195.	1.2	12

#	ARTICLE	IF	CITATIONS
289	Intramedullary spinal cord implantation of human CD34 ⁺ umbilical cord-derived cells in ALS. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</i> , 2011, 12, 325-330.	2.3	12
290	Gene Mutations as Predictive Markers for Postremission Therapy in Younger Adults with Normal Karyotype AML. <i>Blood</i> , 2006, 108, 4-4.	0.6	12
291	Bendamustine Plus Rituximab Followed By Rituximab Maintenance for Patients with Untreated Advanced Follicular Lymphomas. Results from the StiL NHL 7-2008 Trial (MAINTAIN trial) (ClinicalTrials.gov Identifier: NCT00877214). <i>Blood</i> , 2014, 124, 3052-3052.	0.6	12
292	Sustained decrease of peripheral lymphocytes after allogeneic blood stem cell aphereses. <i>British Journal of Haematology</i> , 1998, 100, 695-697.	1.2	11
293	HLA Phenotype and Cytokine-Induced Tumor Control in Advanced Renal Cell Cancer. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2001, 16, 401-409.	0.7	11
294	Expression of the p75 neurotrophin receptor in acute leukaemia. <i>British Journal of Haematology</i> , 2005, 131, 67-70.	1.2	11
295	DNA analysis from stool samples: a fast and reliable method avoiding invasive sampling methods in mouse models of bleeding disorders. <i>Laboratory Animals</i> , 2009, 43, 390-393.	0.5	11
296	Who Is the Best Hematopoietic Stem-Cell Donor for a Male Patient With Acute Leukemia?. <i>Transplantation</i> , 2014, 98, 569-577.	0.5	11
297	Possible Role of Minor H Antigens in the Persistence of Donor Chimerism after Stem Cell Transplantation; Relevance for Sustained Leukemia Remission. <i>PLoS ONE</i> , 2015, 10, e0119595.	1.1	11
298	Transplant outcomes for patients with therapy-related acute myeloid leukemia with prior lymphoid malignancy: an ALWP of EBMT study. <i>Bone Marrow Transplantation</i> , 2020, 55, 224-232.	1.3	11
299	Results of the Randomized Phase II Study Decider (AMLSG 14-09) Comparing Decitabine (DAC) with or without Valproic Acid (VPA) and with or without All-Trans Retinoic Acid (ATRA) Add-on in Newly Diagnosed Elderly Non-Fit AML Patients. <i>Blood</i> , 2016, 128, 589-589.	0.6	11
300	Clinical Results with Recombinant Human Interleukin-3. <i>Cancer Investigation</i> , 1993, 11, 212-218.	0.6	10
301	Clinical and in vitro Response to 13-cis-Retinoic Acid in Interferon-alpha Resistant Renal Cell Carcinoma. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 1997, 12, 143-147.	0.7	10
302	Platelet Glycoprotein Expression in Patients with Myelodysplastic Syndrome. <i>Thrombosis Research</i> , 2000, 100, 27-34.	0.8	10
303	Delayed Distant Spinal Metastasis in Thymomas. <i>Spine</i> , 2013, 38, E1709-E1713.	1.0	10
304	Impaired formation of erythroblastic islands is associated with erythroid failure and poor prognosis in a significant proportion of patients with myelodysplastic syndromes. <i>Haematologica</i> , 2016, 101, e177-e181.	1.7	10
305	Monocytes reprogrammed with lentiviral vectors co-expressing GM-CSF, IFN- γ and antigens for personalized immune therapy of acute leukemia pre- or post-stem cell transplantation. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1891-1899.	2.0	10
306	Allogeneic stem cell transplantation using HLA-matched donors for acute myeloid leukemia with deletion 5q or monosomy 5: a study from the Acute Leukemia Working Party of the EBMT. <i>Haematologica</i> , 2020, 105, 414-423.	1.7	10

#	ARTICLE	IF	CITATIONS
307	Association of Serum Ferritin Levels Before Start of Conditioning With Mortality After alloSCT â€œ A Prospective, Non-interventional Study of the EBMT Transplant Complications Working Party. <i>Frontiers in Immunology</i> , 2020, 11, 586.	2.2	10
308	The impact of cytogenetic risk on the outcomes of allogeneic hematopoietic cell transplantation in patients with relapsed/refractory acute myeloid leukemia: On behalf of the acute leukemia working party (<scp>ALWP</scp>) of the <scp>European group for blood and marrow transplantation (EBMT)</scp>. <i>American Journal of Hematology</i> , 2021, 96, 40-50.	2.0	10
309	Total body irradiation + fludarabine compared to busulfan + fludarabine as â€œreduced-toxicity conditioningâ€œ for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the Acute Leukemia Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 481-491.	1.3	10
310	Distribution of major lymphocyte subsets and memory T-cell subpopulations in healthy adults employing GLP-conforming multicolor flow cytometry. <i>Leukemia</i> , 2021, 35, 3021-3025.	3.3	10
311	Clonal expansion of CD8+ T cells reflects graft-versus-leukemia activity and precedes durable remission following DLI. <i>Blood Advances</i> , 2021, 5, 4485-4499.	2.5	10
312	Improved Outcome for Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) with Poor Risk Cytogenetics â€œ Result from An Analysis on 172 Patients Receiving FLAMSA-RIC Conditioning for Allogeneic Stem Cell Transplantatioin (SCT).. <i>Blood</i> , 2008, 112, 1971-1971.	0.6	10
313	In Acute Myeloid Leukemia with Complex Karyotype TP53 Alterations Are Associated with Specific Genomic Aberrations and Predict Inferior Survival.. <i>Blood</i> , 2009, 114, 2632-2632.	0.6	10
314	Minimal Residual Disease Monitoring in Acute Myeloid Leukemia (AML) with Translocation t(8;21)(q22;q22): Results of the AML Study Group (AMLSC). <i>Blood</i> , 2016, 128, 1207-1207.	0.6	10
315	miR-625-3p is upregulated in CD8+ T cells during early immune reconstitution after allogeneic stem cell transplantation. <i>PLoS ONE</i> , 2017, 12, e0183828.	1.1	10
316	Activation of TRKA receptor elicits mastocytosis in mice and is involved in the development of resistance to KIT-targeted therapy. <i>Oncotarget</i> , 2017, 8, 73871-73883.	0.8	10
317	Continued Treatment with An Outpatient Maintenance Schedule of Decitabine in Older AML Patients Ineligible for Induction Chemotherapy: Results of the 00331 Phase II Multicenter Trial. <i>Blood</i> , 2008, 112, 2965-2965.	0.6	10
318	Competitive Cytokeratin 19 RT-PCR for Quantification of Breast Cancer Cells in Blood Cell Suspensions. <i>Journal of Hematotherapy and Stem Cell Research</i> , 2000, 9, 275-284.	1.8	9
319	Classical Hodgkin’s Lymphoma: Molecular Evidence for Specific Alterations in Circulating T Lymphocytes. <i>Tumor Biology</i> , 2006, 27, 329-333.	0.8	9
320	Targeting vascular endothelial growth factor (VEGF)-receptor-signaling in renal cell carcinoma. <i>World Journal of Urology</i> , 2007, 25, 59-72.	1.2	9
321	<i><scp>ID</scp>1</i> expression associates with other molecular markers and is not an independent prognostic factor in cytogenetically normal acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2012, 158, 208-215.	1.2	9
322	Treating acute promyelocytic leukaemia in Latin America: lessons from the International Consortium on Acute Leukaemia experience. <i>British Journal of Haematology</i> , 2017, 177, 979-983.	1.2	9
323	Cost-effectiveness of methods in personalized medicine. Results of a decision-analytic model in patients with acute myeloid leukemia with normal karyotype. <i>Leukemia Research</i> , 2017, 62, 84-90.	0.4	9
324	Cytomegalovirus-specific CD8+ T-cells are associated with a reduced incidence of early relapse after allogeneic stem cell transplantation. <i>PLoS ONE</i> , 2019, 14, e0213739.	1.1	9

#	ARTICLE	IF	CITATIONS
325	A multicenter prospective, randomized, placebo-controlled phase II/III trial for preemptive acute graft-versus-host disease therapy. <i>Leukemia</i> , 2021, 35, 1763-1772.	3.3	9
326	Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome using treosulfan based compared to other reduced-intensity or myeloablative conditioning regimens. A report of the chronic malignancies working party of the EBMT. <i>British Journal of Haematology</i> , 2021, 195, 417-428.	1.2	9
327	Bendamustine Plus Rituximab (B-R) Versus CHOP Plus Rituximab (CHOP-R) As First-Line Treatment in Patients with Indolent and Mantle Cell Lymphomas (MCL) – 7 Year Updated Results from the StiL NHL1 Study. <i>Blood</i> , 2014, 124, 4407-4407.	0.6	9
328	Outcome of Third Salvage Autologous Stem Cell Transplantation in Multiple Myeloma. <i>Blood</i> , 2016, 128, 993-993.	0.6	9
329	Neurological management and work-up of neurotoxicity associated with CAR T cell therapy. <i>Neurological Research and Practice</i> , 2022, 4, 1.	1.0	9
330	The deletion polymorphism in the angiotensin-converting enzyme gene is a moderate risk factor for venous thromboembolism. <i>Thrombosis and Haemostasis</i> , 2003, 89, 847-52.	1.8	9
331	Functional Analysis of a Single Chain Chimeric $\alpha\beta$ -Granulocyte-Macrophage Colony-stimulating Factor Receptor. <i>Journal of Biological Chemistry</i> , 1999, 274, 33064-33071.	1.6	8
332	Erythropoietin in cancer-related anemia. <i>Current Opinion in Oncology</i> , 2008, 20, 685-689.	1.1	8
333	Evaluation of Tissue Factor Bearing Microparticles as Biomarkers in Allogeneic Stem-Cell Transplantation. <i>Transplantation</i> , 2011, 92, 351-358.	0.5	8
334	P-selectin glycoprotein ligand-1 positive microparticles in allogeneic stem cell transplantation of hematologic malignancies. <i>Experimental Hematology</i> , 2011, 39, 1047-1055.	0.2	8
335	Activation of TRKB receptor in murine hematopoietic stem/progenitor cells induced mastocytosis. <i>Blood</i> , 2014, 124, 1196-1197.	0.6	8
336	The stem cell zinc finger 1 (SZF1)/ZNF589 protein has a human-specific evolutionary nucleotide DNA change and acts as a regulator of cell viability in the hematopoietic system. <i>Experimental Hematology</i> , 2016, 44, 257-268.	0.2	8
337	Clinical impact of BAALC expression in high-risk acute promyelocytic leukemia. <i>Blood Advances</i> , 2017, 1, 1807-1814.	2.5	8
338	Routes of Clonal Evolution into Complex Karyotypes in Myelodysplastic Syndrome Patients with 5q Deletion. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3269.	1.8	8
339	Focusing of the regulatory T-cell repertoire after allogeneic stem cell transplantation indicates protection from graft-versus-host disease. <i>Haematologica</i> , 2019, 104, e577-e580.	1.7	8
340	Meningioma 1 is indispensable for mixed lineage leukemia-rearranged acute myeloid leukemia. <i>Haematologica</i> , 2020, 105, 1294-1305.	1.7	8
341	Hepatosplenic candidiasis in patients with acute leukaemia. <i>British Journal of Haematology</i> , 2000, 109, 672-672.	1.2	8
342	Hematopoietic growth factors in the treatment of the myelodysplastic syndromes. <i>Current Opinion in Hematology</i> , 1995, 2, 204-209.	1.2	8

#	ARTICLE	IF	CITATIONS
343	Improved Health-Related Quality of Life in Patients with Hematological Disorders Receiving Deferasirox (Exjade®). <i>Blood</i> , 2008, 112, 1307-1307.	0.6	8
344	A Novel Inhibitor of Mutant IDH1 Induces Differentiation in Vivo and Prolongs Survival in a Mouse Model of Leukemia. <i>Blood</i> , 2014, 124, 3598-3598.	0.6	8
345	Adaptive NK cells undergo a dynamic modulation in response to human cytomegalovirus and recruit T cells in in vitro migration assays. <i>Bone Marrow Transplantation</i> , 2022, 57, 712-720.	1.3	8
346	Impact of in vivo T-cell depletion in patients with myelodysplastic syndromes undergoing allogeneic hematopoietic stem cell transplant: a registry study from the Chronic Malignancies Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2022, 57, 768-774.	1.3	8
347	Cytological characterization of murine bone marrow and spleen hematopoietic compartments for improved assessment of toxicity in preclinical gene marking models. <i>Annals of Hematology</i> , 2013, 92, 595-604.	0.8	7
348	Long-term results of a prospective randomized trial evaluating G-CSF priming in intensive induction chemotherapy followed by autologous stem cell transplantation in elderly patients with acute myeloid leukemia. <i>Annals of Hematology</i> , 2014, 93, 193-202.	0.8	7
349	Outcome of Allogeneic Stem Cell Transplantation for Patients Transformed to Myelodysplastic Syndrome or Leukemia from Severe Aplastic Anemia: A Report from the MDS Subcommittee of the Chronic Malignancies Working Party and the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1448-1459.	2.0	7
350	Deletion or inhibition of Fc gamma receptor 2B (CD32) prevents FVIII-specific activation of memory B cells in vitro. <i>Thrombosis and Haemostasis</i> , 2015, 114, 1127-1135.	1.8	7
351	Peripheral blood cytogenetics allows treatment monitoring and early identification of treatment failure to lenalidomide in MDS patients: results of the LE-MON-5 trial. <i>Annals of Hematology</i> , 2017, 96, 887-894.	0.8	7
352	The hypomorphic TERT A1062T variant is associated with increased treatment-related toxicity in acute myeloid leukemia. <i>Annals of Hematology</i> , 2017, 96, 895-904.	0.8	7
353	The impact of concomitant cytogenetic abnormalities on acute myeloid leukemia with monosomy 7 or deletion 7q after HLA-matched allogeneic stem cell transplantation. <i>American Journal of Hematology</i> , 2020, 95, 282-294.	2.0	7
354	Reduced SLIT2 is Associated with Increased Cell Proliferation and Arsenic Trioxide Resistance in Acute Promyelocytic Leukemia. <i>Cancers</i> , 2020, 12, 3134.	1.7	7
355	Inferior Outcome of Allogeneic Stem Cell Transplantation in First Complete Remission for Secondary AML As Compared to De Novo Disease: Results from a Retrospective, Registry-Based Analysis on Behalf of the Acute Leukemia Working Party of the EBMT. <i>Blood</i> , 2018, 132, 2166-2166.	0.6	7
356	Event-Free Survival Is a Surrogate for Overall Survival in Patients Treated for Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 3744-3744.	0.6	7
357	Pan-Mutant-IDH1 Inhibitor Bay-1436032 Is Highly Effective Against Human IDH1 Mutant Acute Myeloid Leukemia In Vivo. <i>Blood</i> , 2016, 128, 745-745.	0.6	7
358	VH1 Family Immunoglobulin Repertoire Sequencing after Allogeneic Hematopoietic Stem Cell Transplantation. <i>PLoS ONE</i> , 2017, 12, e0168096.	1.1	7
359	Hepatic toxicity during regorafenib treatment in patients with metastatic gastrointestinal stromal tumors. <i>Molecular and Clinical Oncology</i> , 2020, 13, 1-1.	0.4	7
360	Acute Myeloid Leukemia (AML) with 9q Aberrations Occuring within a Non-Complex Karyotype Is Highly Associated with CEBPA and NPM1 Mutations - A Joint Analysis of the German-Austrian AML Study Group (AMLSC) and Cancer and Leukemia Group B (CALGB).. <i>Blood</i> , 2007, 110, 762-762.	0.6	7

#	ARTICLE	IF	CITATIONS
361	Amplified <i>EPOR</i> / <i>JAK2</i> Genes Define a Unique Subtype of Acute Erythroid Leukemia. <i>Blood Cancer Discovery</i> , 2022, 3, 410-427.	2.6	7
362	CFUaECM:CFUaECM MIX RATION INTHE PERIPHERAL BLOOD AND BONE MARROW AND ITS IMPORTANCE IN AUTOLOGOUS TRANSPLANTATION OF CIRCULATING STEAM CELLS. <i>British Journal of Haematology</i> , 1986, 64, 628-629.	1.2	6
363	Detection of melanoma cells in peripheral blood stem cell harvests of patients with progressive metastatic malignant melanoma. <i>British Journal of Haematology</i> , 1997, 98, 488-491.	1.2	6
364	Molecular pathogenesis of acute myeloid leukemia: A diverse disease with new perspectives. <i>Frontiers of Medicine in China</i> , 2010, 4, 356-362.	0.1	6
365	Leukemias induced by altered TRK-signaling are sensitive to mTOR inhibitors in preclinical models. <i>Annals of Hematology</i> , 2011, 90, 283-292.	0.8	6
366	Birth Order and Transplantation Outcome in HLA-Identical Sibling Stem Cell Transplantation: An Analysis on Behalf of the Center for International Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 741-745.	2.0	6
367	Lack of noncanonical RAS mutations in cytogenetically normal acute myeloid leukemia. <i>Annals of Hematology</i> , 2014, 93, 977-982.	0.8	6
368	Letter to the Editor: Production of Mature Healthy Hematopoietic Cells from Induced Pluripotent Stem Cells Derived from an AML Diagnostic Sample Containing the t(8;21) Translocation. <i>Stem Cells</i> , 2016, 34, 797-799.	1.4	6
369	Therapy of Treatment-Related Hypertension in Metastatic Renal-Cell Cancer Patients Receiving Sunitinib. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 280-290.e3.	0.9	6
370	Severe allo-immune antibody-associated peripheral and central nervous system diseases after allogeneic hematopoietic stem cell transplantation. <i>Scientific Reports</i> , 2021, 11, 8527.	1.6	6
371	Late Consolidation for Patients with Standard Risk AML up to 60 Years: Results of a Prospective Randomized Comparison of High Dose AraC and Autologous PBSCT.. <i>Blood</i> , 2004, 104, 145-145.	0.6	6
372	Treatment of Patients up to 60 Years with High Risk AML: Final Results of the AML SHG-Hannover 01/99 Trial.. <i>Blood</i> , 2006, 108, 433-433.	0.6	6
373	Satisfaction and Adherence Significantly Improves in Patients with β^2 -Thalassemia and Myelodysplastic Syndromes Treated with Deferasirox (Exjade®). <i>Blood</i> , 2008, 112, 1306-1306.	0.6	6
374	New Definition of Treatment Response in Adult Acute Lymphoblastic Leukemia (ALL): Use of Molecular Markers for Minimal Residual Disease (MRD).. <i>Blood</i> , 2009, 114, 90-90.	0.6	6
375	Long Term Follow-up of 121 Elderly Patients with Philadelphia-Positive Acute Lymphoblastic Leukaemia (Ph+ALL) Treated in Prospective GMALL Trials Supports a Greater Emphasis On Allogeneic SCT as Definitive Postremission Therapy.. <i>Blood</i> , 2012, 120, 2608-2608.	0.6	6
376	Pharmacodynamic Monitoring of the Efficacy of a Targeted Therapy with Midostaurin By Plasma Inhibitor Activity (PIA) Analysis in FLT3 -ITD Positive AML Patients within the AMLSG 16-10 Trial: A Study of the AML Study Group (AMLSG). <i>Blood</i> , 2015, 126, 2585-2585.	0.6	6
377	Tumor Cell-Based Vaccination in Renal Cell Carcinoma: Rationale, Approaches, and Recent Clinical Development. <i>Current Drug Targets</i> , 2002, 3, 401-408.	1.0	6
378	Outcome of Older AML Patients with Adverse Cytogenetics, Including Single or Multiple Monosomies, Treated with the DNA Hypomethylating Agent Decitabine. <i>Blood</i> , 2011, 118, 2609-2609.	0.6	6

#	ARTICLE	IF	CITATIONS
379	NADH Dehydrogenase Subunit 4 (ND4) Mutations in Pediatric Acute Myeloid Leukemia. <i>Blood</i> , 2012, 120, 1380-1380.	0.6	6
380	A unique role of p53 haploinsufficiency or loss in the development of acute myeloid leukemia with FLT3-ITD mutation. <i>Leukemia</i> , 2021, , .	3.3	6
381	Comparative Evaluation of Commonly Used Clones and Fluorochrome Conjugates of Monoclonal Antibodies for CD34 Antigen Detection. <i>Journal of Hematotherapy and Stem Cell Research</i> , 1999, 8, 547-559.	1.8	5
382	Receptor-Mediated Endocytosis of CD34 on Hematopoietic Cells after Stimulation with the Monoclonal Antibody Anti-HPCA-1. <i>Journal of Hematotherapy and Stem Cell Research</i> , 2001, 10, 863-871.	1.8	5
383	High cut-off dialysis as a salvage therapy option in high-dose methotrexate chemotherapy?. <i>Annals of Hematology</i> , 2014, 93, 1053-1055.	0.8	5
384	Explaining survival differences between two consecutive studies with allogeneic stem cell transplantation in patients with chronic myeloid leukemia. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 1367-1381.	1.2	5
385	Expression of the ETS transcription factor GABP± is positively correlated to the BCR-ABL1/ABL1 ratio in CML patients and affects imatinib sensitivity in vitro. <i>Experimental Hematology</i> , 2015, 43, 880-890.	0.2	5
386	Differential Effects of Gut-Homing Molecules CC Chemokine Receptor 9 and Integrin-Î²7 during Acute Graft-versus-Host Disease of the Liver. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2069-2078.	2.0	5
387	Impact of complete surgical resection on outcome in aggressive non-Hodgkin lymphoma treated with immunochemotherapy. <i>Cancer Medicine</i> , 2020, 9, 8386-8396.	1.3	5
388	Association of uric acid levels before start of conditioning with mortality after allogeneic hematopoietic stem cell transplantation – a prospective, non-interventional study of the EBMT Transplant Complication Working Party. <i>Haematologica</i> , 2020, 105, 1977-1983.	1.7	5
389	NTAL is associated with treatment outcome, cell proliferation and differentiation in acute promyelocytic leukemia. <i>Scientific Reports</i> , 2020, 10, 10315.	1.6	5
390	Cluster of differentiation 33 single nucleotide polymorphism rs12459419 is a predictive factor in patients with nucleophosmin1 mutated acute myeloid leukemia receiving gemtuzumab ozogamicin. <i>Haematologica</i> , 2021, 106, 2986-2989.	1.7	5
391	Induced dendritic cells co-expressing GM-CSF/IFN-Î±/TWT1 priming T and B cells and automated manufacturing to boost GvL. <i>Molecular Therapy - Methods and Clinical Development</i> , 2021, 21, 621-641.	1.8	5
392	Comparison of long-term outcome for AML patients alive free of disease 2 years after allogeneic hematopoietic cell transplantation with umbilical cord blood versus unrelated donor: a study from the ALWP of the EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 2742-2748.	1.3	5
393	Case Report: Convalescent Plasma Therapy Induced Anti-SARS-CoV-2 T Cell Expansion, NK Cell Maturation and Virus Clearance in a B Cell Deficient Patient After CD19 CART Cell Therapy. <i>Frontiers in Immunology</i> , 2021, 12, 721738.	2.2	5
394	Gemtuzumab Ozogamicin in NPM1-Mutated Acute Myeloid Leukemia (AML): Results from the Prospective Randomized AMLSG 09-09 Phase-III Study. <i>Blood</i> , 2018, 132, 81-81.	0.6	5
395	Allogeneic Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia (CLL) with 17p Deletion: A Retrospective EBMT Analysis.. <i>Blood</i> , 2007, 110, 47-47.	0.6	5
396	Sunitinib and Intensive Chemotherapy in Patients with Acute Myeloid Leukemia and Activating FLT3 Mutations: Results of the AMLSG 10-07 Study (ClinicalTrials.gov No. NCT00783653). <i>Blood</i> , 2012, 120, 1483-1483.	0.6	5

#	ARTICLE	IF	CITATIONS
397	Improved Outcome with ATRA-Arsenic Trioxide Compared to ATRA-Chemotherapy in Non-High Risk Acute Promyelocytic Leukemia – Updated Results of the Italian-German APL0406 Trial on the Extended Final Series. <i>Blood</i> , 2014, 124, 12-12.	0.6	5
398	Molecular Predictors of Outcome in Patients with MDS and AML Following MDS after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2015, 126, 912-912.	0.6	5
399	Condensed Versus Standard Schedule of High-Dose Cytarabine Consolidation Therapy with Pegfilgrastim Growth Factor Support in Acute Myeloid Leukemia. <i>Blood</i> , 2016, 128, 337-337.	0.6	5
400	Diagnostic Workup of Patients with Acquired Von Willebrand™s Syndrome.. <i>Blood</i> , 2006, 108, 1045-1045.	0.6	5
401	Myelodysplastic Syndromes. <i>BioDrugs</i> , 1998, 10, 97-109.	2.2	4
402	Persistent aplasia after chemotherapy for acute myeloid leukaemia treated with stem cell transplantation from a matched unrelated donor after dose-reduced conditioning. <i>British Journal of Haematology</i> , 2002, 118, 442-444.	1.2	4
403	Antigen-recognition sites of micromanipulated T cells in patients with acquired aplastic anemia. <i>Experimental Hematology</i> , 2005, 33, 804-810.	0.2	4
404	Quantification of transforming capacity and cooperation of defined genetic alterations in myeloid malignancies. <i>Experimental Hematology</i> , 2010, 38, 11-19.	0.2	4
405	Reply to I.H.I.M. Hollink et al. <i>Journal of Clinical Oncology</i> , 2010, 28, e527-e528.	0.8	4
406	miR-125b regulates chemotaxis and survival of bone marrow derived granulocytes in vitro and in vivo. <i>PLoS ONE</i> , 2018, 13, e0204942.	1.1	4
407	Stable depletion of RUNX1-ETO in Kasumi-1 cells induces expression and enhanced proteolytic activity of Cathepsin G and Neutrophil Elastase. <i>PLoS ONE</i> , 2019, 14, e0225977.	1.1	4
408	Outcomes and toxicity of allogeneic hematopoietic cell transplantation in chronic myeloid leukemia patients previously treated with second-generation tyrosine kinase inhibitors: a prospective non-interventional study from the Chronic Malignancy Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2022, 57, 23-30.	1.3	4
409	Validation of a Frailty Score Predicting Survival of Elderly, Non-Fit AML Patients Receiving Hypomethylating Therapy: Results of the Decider Trial. <i>Blood</i> , 2018, 132, 720-720.	0.6	4
410	Hemostatic Alterations in Patients Undergoing Hematopoietic Stem Cell Transplantation.. <i>Blood</i> , 2004, 104, 985-985.	0.6	4
411	Postremission Therapy with an Allogeneic Transplantation from an HLA-Matched Family Donor Seems To Overcome the Negative Prognostic Impact of FLT3-ITD in Younger Patients with Acute Myeloid Leukemia Exhibiting a Normal Karyotype.. <i>Blood</i> , 2005, 106, 2353-2353.	0.6	4
412	Valproic Acid as Adjunct to Induction Therapy in Patients with Acute Myeloid Leukemia: First Results of Two Randomized Studies of the AMLSG.. <i>Blood</i> , 2005, 106, 2800-2800.	0.6	4
413	The High Prevalence of FLT3-ITD Mutations Is Associated with the Poor Outcome in Adult Patients with t(6;9)(p23;q34) Positive AML - Results of an International Metaanalysis.. <i>Blood</i> , 2007, 110, 761-761.	0.6	4
414	Iron Chelation in Regularly Transfused Patients with Aplastic Anemia: Efficacy and Safety Results from the Large Deferasirox EPIC Trial. <i>Blood</i> , 2008, 112, 439-439.	0.6	4

#	ARTICLE	IF	CITATIONS
415	TP53 Alterations in Acute Myeloid Leukemia with Complex Karyotype Correlate with Specific Copy Number Alterations, Monosomal Karyotype, and Dismal Outcome., Blood, 2011, 118, 3558-3558.	0.6	4
416	Monitoring of Minimal Residual Disease (MRD) of DNMT3A Mutations (DNMT3A _{mut}) in Acute Myeloid Leukemia (AML): A Study of the AML Study Group (AMLSG). Blood, 2015, 126, 226-226.	0.6	4
417	Flow cytometric characterization of acute leukemia reveals a distinctive "blast gate" of murine T-lymphoblastic leukemia/lymphoma. Oncotarget, 2018, 9, 2320-2328.	0.8	4
418	Tissue-Factor- and PSGL-1-Bearing Microparticles Are Strong Outcome Predictors in Allogeneic Stem Cell Transplantation.. Blood, 2009, 114, 2263-2263.	0.6	4
419	Retrospective Comparison between 12-Gray and 8-Gray Total Body Irradiation (TBI) before Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Lymphoblastic Leukemia in First Complete Remission. Blood, 2021, 138, 1783-1783.	0.6	4
420	Allogeneic hematopoietic cell transplantation in patients with therapy-related myeloid neoplasm after breast cancer: a study of the Chronic Malignancies Working Party of the EBMT. Bone Marrow Transplantation, 2022, 57, 1072-1078.	1.3	4
421	Mixed megakaryocytic-granulocytic differentiation during diffusion chamber culture of peripheral blast cells from the blast crisis of chronic myelocytic leukemia. Leukemia Research, 1985, 9, 1031-1041.	0.4	3
422	A Comparative Review of Methods for T Cell Depletion in the Prophylaxis of Graft-versus-Host Disease. BioDrugs, 1998, 9, 105-123.	2.2	3
423	Analysis of the Nuclear Distribution of the Translocation t(8;21)-Derived Fusion Protein AML1/ETO by Confocal Laser Scanning Microscopy. Journal of Hematotherapy and Stem Cell Research, 2002, 11, 401-408.	1.8	3
424	Cross-trial networking in AML: a step forward rather than corner cutting. Leukemia Research, 2004, 28, 649-650.	0.4	3
425	Secondary AML Is an Independent Risk Factor for Outcome after SCT in First Complete Remission - a Registry-Based Comparison to De Novo AML on Behalf of the EBMT Acute Leukemia Working Party. Biology of Blood and Marrow Transplantation, 2019, 25, S11.	2.0	3
426	Evaluation of six different types of sequential conditioning regimens for allogeneic stem cell transplantation in relapsed/refractory acute myelogenous leukemia " a study of the Acute Leukemia Working Party of the EBMT. Leukemia and Lymphoma, 2021, 62, 399-409.	0.6	3
427	Monitoring of FLT3 Phosphorylation and FLT3 Ligand Levels in Patients with FLT3-ITD Mutated Acute Myeloid Leukemia (AML) Treated with Midostaurin within the AMLSG 16-10 Trial of the German-Austrian Study Group. Blood, 2018, 132, 1501-1501.	0.6	3
428	Prognostic Impact of Insertion Site in Acute Myeloid Leukemia (AML) with FLT3 Internal Tandem Duplication: Results from the Ratify Study (Alliance 10603). Blood, 2018, 132, 435-435.	0.6	3
429	Long Term Remission in Follicular Lymphoma (FL) and Mantle Cell Lymphoma (MCL) with Rituximab Consolidation after High-Dose Chemotherapy and Autologous Stem Cell Transplantation: Extended Follow-Up of a Multicenter Phase II Study.. Blood, 2005, 106, 2078-2078.	0.6	3
430	No Elevated Rates of Treatment-Related Myelodysplastic Syndromes and Second Solid Tumors Following Therapy with Bendamustine Compared with Other Anti-Lymphoma Regimes for Low-Grade Non-Hodgkin's Lymphoma. Blood, 2010, 116, 3090-3090.	0.6	3
431	Prognostic Effect of Mutations in the Splicing Gene Machinery in 339 Patients with MDS or Secondary AML Following MDS After Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2012, 120, 357-357.	0.6	3
432	Azacitidine-Containing Induction Regimens Followed by Azacitidine Maintenance Therapy in High Risk Acute Myeloid Leukemia: First Results of the Randomized Phase-II AMLSG 12-09 Study (ClinicalTrials.gov) Tj ETQq0000 rgBT /@verlock 1		

#	ARTICLE	IF	CITATIONS
433	Pharmacodynamic Analysis Of The Inhibitory Potency Of The Tyrosine Kinase Inhibitor Midostaurin In Combination With Intensive Chemotherapy Including Allogeneic Hematopoietic Stem Cell Transplantation Followed By Maintenance Therapy In FLT3-ITD Positive Acute Myeloid Leukemia In The Ongoing AMLSG 16-10 Trial. <i>Blood</i> , 2013, 122, 1283-1283.	0.6	3
434	Low-Dose Decitabine Vs Best Supportive Care In Older Patients With AML and Low Blast Counts: Results Of a Subgroup Analysis Of The Randomized Phase III Study 06011 Of The EORTC Leukemia Cooperative Group and German MDS Study Group. <i>Blood</i> , 2013, 122, 1452-1452.	0.6	3
435	Targeted Inhibition of the NUP98-NSD1 Fusion Oncogene in AML. <i>Blood</i> , 2019, 134, 2545-2545.	0.6	3
436	Genotype-Phenotype Relationships and Therapeutic Targets in Acute Erythroid Leukemia. <i>Blood</i> , 2020, 136, 17-18.	0.6	3
437	Cardiac surgery in a patient with paroxysmal nocturnal hemoglobinuria. <i>Haematologica</i> , 2002, 87, ECR29.	1.7	3
438	Key Data Elements in Myeloid Leukemia. <i>Studies in Health Technology and Informatics</i> , 2016, 228, 282-6.	0.2	3
439	Evolution of severe (transfusionâ€dependent) anaemia in myelodysplastic syndromes with 5q deletion is characterized by a macrophageâ€associated failure of the erythropoietic niche. <i>British Journal of Haematology</i> , 2022, , .	1.2	3
440	Detection of chronic systemic candida infection in leukaemia patients with febrile neutropenia: value of computerâ€assisted serial ultrasound documentation. <i>European Journal of Haematology</i> , 1998, 60, 320-321.	1.1	2
441	Complete cytogenetic remission after decitabine treatment in a patient with secondary AML harbouring high p15 INK4b gene methylation and high global DNA methylation. <i>Annals of Hematology</i> , 2009, 88, 275-277.	0.8	2
442	Treatment with tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma is associated with drug-induced hyperparathyroidism: a single center experience in 59 patients. <i>World Journal of Urology</i> , 2010, 28, 311-317.	1.2	2
443	Reply to S. Masuda. <i>Journal of Clinical Oncology</i> , 2011, 29, 4593-4594.	0.8	2
444	CT patterns of organizing pneumonia in patients treated with VEGF/mTOR inhibitors for metastatic renal cell cancer: an observational study. <i>Acta Radiologica Open</i> , 2017, 6, 205846011769421.	0.3	2
445	Phase II<sc>II</sc> study on cytarabine and idarubicin combined with escalating doses of clofarabine in newly diagnosed patients with acute myeloid leukaemia and high risk for induction failure (<sc>AMLSG</sc> 17â€10 <sc>CIARA</sc> trial). <i>British Journal of Haematology</i> , 2018, 183, 235-241.	1.2	2
446	Cumulative dosages of chemotherapy and radiotherapy exposure, and risk of secondary malignancies after allogeneic hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2019, 54, 635-640.	1.3	2
447	Adenosine stress perfusion cardiac magnetic resonance imaging in patients undergoing intracoronary bone marrow cell transfer after ST-elevation myocardial infarction: the BOOST-2 perfusion substudy. <i>Clinical Research in Cardiology</i> , 2020, 109, 539-548.	1.5	2
448	Functional and clinical characterization of the alternatively spliced isoform AML1-ETO9a in adult patients with translocation t(8;21)(q22;q22.1) acute myeloid leukemia (AML). <i>Leukemia</i> , 2020, 34, 630-634.	3.3	2
449	Impact of <sc><i>PPM1D</i></sc> mutations in patients with myelodysplastic syndrome and deletion of chromosome 5q. <i>American Journal of Hematology</i> , 2021, 96, E207-E210.	2.0	2
450	Post Transplantation Measurable Residual Disease (MRD) Monitoring Using Next-Generation Sequencing Is Highly Predictive for Relapseafter Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2019, 134, 184-184.	0.6	2

#	ARTICLE	IF	CITATIONS
451	Treatment of Adult Patients with High Risk Acute Myeloblastic Leukemia up to 60 Years: Role of Consolidation Therapy within a Prospective Multicenter Trial.. Blood, 2004, 104, 618-618.	0.6	2
452	Prognosis of Adult Patients < Years with AML and Aberrations of Chromosome 11q23: Pooled Data Analysis of the AML-SG and SHG-Dresden Study Groups.. Blood, 2005, 106, 2360-2360.	0.6	2
453	Prognosis of Adult Patients < Years with AML and Aberrations of Chromosome 11q23: Pooled Data Analysis of the German AML-Intergroup.. Blood, 2006, 108, 16-16.	0.6	2
454	Priming with Granulocyte-Colony Stimulating Factor Did Not Improve Outcome in a Randomized Study of Elderly Acute Myeloid Leukemia but Increased Induction Mortality.. Blood, 2006, 108, 1980-1980.	0.6	2
455	Immunosuppression for Patients with Low and Intermediate Risk Myelodysplastic Syndrome: A Prospective Randomized Multicenter Trial Comparing Antithymocyte Globulin + Cyclosporine with Best Supportive Care: SAKK 33/99.. Blood, 2007, 110, 1461-1461.	0.6	2
456	Clinical Impact of WT1 Mutations in the Context of Other Molecular Markers in Cytogenetically Normal Acute Myeloid Leukemia (AML): A Study of the German-Austrian AML Study Group (AMLSC).. Blood, 2007, 110, 364-364.	0.6	2
457	Lower Relapse Incidence and Relapse Mortality in Patients Transplanted from a Younger Sibling in HLA-Identical Stem Cell Transplantation: Does Microchimerism Matter?. Blood, 2008, 112, 343-343.	0.6	2
458	Low-Dose Decitabine (DAC), Alone or in Combination with All-Trans Retinoic Acid (ATRA), Is An Active First-Line Treatment in Older AML Patients of All Cytogenetic Risk Groups: Final Results of the FR00331 Multicenter Phase II Study.. Blood, 2009, 114, 4141-4141.	0.6	2
459	Type and Number of Secondary Molecular Lesions Improve Outcome Prediction in Acute Myeloid Leukemia (AML) with inv(16) or t(16;16): A Study of the German-Austrian AML Study Group (AMLSC).. Blood, 2009, 114, 824-824.	0.6	2
460	Prognostic Effect of ASXL1 Mutations in Patients with MDS and Secondary AML Following MDS After Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2011, 118, 1709-1709.	0.6	2
461	Clinical Impact of TERT A1062T Mutations in Younger Patients with Acute Myeloblastic Leukemia. Blood, 2012, 120, 1381-1381.	0.6	2
462	ZRSR2 Mutations Cause Dysregulated RNA Splicing in MDS. Blood, 2014, 124, 4609-4609.	0.6	2
463	Effective Treatment of Human CML By RNAi In Vivo in a Xenotransplantation Mouse Model. Blood, 2015, 126, 1261-1261.	0.6	2
464	The EBMT Score Predicts Transplant Related Mortality and Overall Survival after Allogeneic Stem Cell Transplantation for Myelodysplastic Syndromes. Blood, 2015, 126, 3223-3223.	0.6	2
465	Impact of Molecular Genetics on Disease-Free Survival in Myelofibrosis Patients Following Allogeneic Stem Cell Transplantation. Blood, 2015, 126, 352-352.	0.6	2
466	Dissecting Genetic and Phenotypic Heterogeneity to Map Molecular Phylogenies and Deliver Personalized Outcome and Treatment Predictions in AML. Blood, 2015, 126, 803-803.	0.6	2
467	TCR Diversity Is a Predictive Marker for Donor Lymphocyte Infusion Response. Blood, 2016, 128, 4605-4605.	0.6	2
468	Immunosuppressive Therapy for Myelodysplastic Syndromes. Current Pharmaceutical Design, 2012, 18, 3184-3189.	0.9	2

#	ARTICLE	IF	CITATIONS
469	Frequency and Prognostic Impact of NUP98/NSD1 Translocations in Adult AML and MDS Patients. <i>Blood</i> , 2012, 120, 1402-1402.	0.6	2
470	Allogeneic Hematopoietic Stem-Cell Transplantation (HSCT) in First Complete Remission Is Superior Compared to Chemotherapy/Autologous HSCT in Patients with Intermediate-Risk Cytogenetics Acute Myeloid Leukemia Lacking Mutations in NPM1, FLT3-ITD, and CEBPA: A Joint Study of AMLSG, Cetlam and Acute Leukemia Working Party of EBMT. <i>Blood</i> , 2014, 124, 324-324.	0.6	2
471	Allogeneic, CD34 +, Umbilical Cordblood-Derived NK Cell Adoptive Immunotherapy for the Treatment of Acute Myeloid Leukemia Patients with Measurable Residual Disease. <i>Blood</i> , 2021, 138, 1745-1745.	0.6	2
472	EPOR/JAK/STAT Signaling Pathway As Therapeutic Target of Acute Erythroid Leukemia. <i>Blood</i> , 2021, 138, 610-610.	0.6	2
473	Randomized Phase II Study of All- <i>Trans</i> Retinoic Acid and Valproic Acid Added to Decitabine in Newly Diagnosed Elderly AML Patients (DECIDER trial): Predictive Impact of <i>TP53</i> Status. <i>Blood</i> , 2021, 138, 2380-2380.	0.6	2
474	Prognostic value of a new clinically-based classification system in patients with CMML undergoing allogeneic HCT: a retrospective analysis of the EBMT-CMWP. <i>Bone Marrow Transplantation</i> , 2022, 57, 896-902.	1.3	2
475	In vitro differentiation of a null-acute leukemia: T-lymphoid surface antigen expression associated with rearrangement in T-cell receptor beta chain variable genes. <i>Cancer Genetics and Cytogenetics</i> , 1987, 28, 327-334.	1.0	1
476	Safety, Feasibility and Therapeutic Activity of Intrapleural Autologous Lymphocyte Conditioned Medium Followed by Systemic Recombinant Interleukin-2 and Interferon- γ in a Patient with Malignant Pleural Mesothelioma. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 1997, 12, 141-142.	0.7	1
477	Elevated Plasma Levels of Interleukin-1 Receptor Antagonist are Associated with Decreased Cellular BCL-2 Oncoprotein Expression in B-Chronic Lymphocytic Leukemia. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 1998, 13, 383-385.	0.7	1
478	Acral Necrosis after Inadequate Excessive Administration of Bleomycin in a Testicular Cancer Patient. <i>Oncology Research and Treatment</i> , 2005, 28, 41-43.	0.8	1
479	Going from genes to proteins in myelodysplastic syndromes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 1109-1110.	3.3	1
480	Immunosuppressive treatment strategies in low-risk MDS. <i>Cancer Treatment Reviews</i> , 2007, 33, S11-S14.	3.4	1
481	Genetic changes of miR-182 G106A: rather a polymorphism than a somatic mutation. <i>Annals of Hematology</i> , 2011, 90, 1107-1109.	0.8	1
482	Predicting death in patients with acute graft-versus-host disease after reduced-intensity conditioning. <i>Lancet Haematology</i> , 2017, 4, e400-e401.	2.2	1
483	Histiocytic sarcoma progressing from follicular lymphoma and mimicking acquired hemophagocytic lymphohistiocytosis. <i>Annals of Hematology</i> , 2020, 99, 2441-2443.	0.8	1
484	Proteomics for hematopoietic stem cell transplantation. <i>Expert Review of Proteomics</i> , 2020, 17, 201-206.	1.3	1
485	Allogeneic hematopoietic cell transplantation (allo-HCT) outcomes in myeloma patients on renal replacement therapy: a report from the Chronic Malignancy Working Party (CMWP) of the European Society of Blood and Marrow Transplantation (EBMT). <i>Bone Marrow Transplantation</i> , 2021, 56, 529-531.	1.3	1
486	Prognostic role of docetaxel-induced suppression of free testosterone serum levels in metastatic prostate cancer patients. <i>Scientific Reports</i> , 2021, 11, 16457.	1.6	1

#	ARTICLE	IF	CITATIONS
487	The Role of PPM1D Mutations in Lenalidomide Resistance and Progression in Patients with MDS and Deletion of Chromosome 5q. <i>Blood</i> , 2018, 132, 4360-4360.	0.6	1
488	Comprehensive Molecular Profiling of FLT3-Mutated Acute Myeloid Leukemia (AML) Patients Treated within the Ratify Trial (Alliance C10603). <i>Blood</i> , 2018, 132, 1534-1534.	0.6	1
489	Novel Molecular Pathogenesis and Therapeutic Target in Acute Erythroid Leukemia. <i>Blood</i> , 2019, 134, 914-914.	0.6	1
490	Acquired Hemophilia Caused by Non-Hemophilic Factor VIII Gene Variants.. <i>Blood</i> , 2004, 104, 3083-3083.	0.6	1
491	Valproic Acid Induces Cell Cycle Arrest and Differentiation of t(15;17) Positive Leukemic Cells Independent from ATRA Sensitivity and Has No Effect on CD34pos Cells.. <i>Blood</i> , 2005, 106, 2834-2834.	0.6	1
492	In CML, Marrow Fibrosis Relapses or Emerges in 5 - 6 % of Patients Per Year Independently Indicating Imatinib Failure and Shortened Survival Time of Patients.. <i>Blood</i> , 2006, 108, 2195-2195.	0.6	1
493	The Polycistronic miRNA Cluster miR-17-92 Is Over-Expressed in Early Phase Chronic Myeloid Leukemia (CML) CD34+ Cells.. <i>Blood</i> , 2006, 108, 741-741.	0.6	1
494	Comparable Outcome after Allogeneic Hematopoietic Cell Transplantation from Matched Unrelated and Sibling Donors in Elderly Patients with Acute Myeloid Leukemia - Results of a Retrospective Analysis in 368 Patients.. <i>Blood</i> , 2007, 110, 172-172.	0.6	1
495	RUNX1 Mutations in Acute Myeloid Leukemia (AML): Correlation with Distinct Cytogenetic Subgroups and Clinical Outcome. Results of the AML Study Group (AMLSG). <i>Blood</i> , 2008, 112, 145-145.	0.6	1
496	Extramedullary Acute Leukemias prior to and after Allogeneic Hematopoietic Stem Cell Transplantation: a Single Center Study.. <i>Blood</i> , 2008, 112, 3262-3262.	0.6	1
497	Analysis of the ETS Family Member Genes ERG, ETS2, ETS1 and FLI1 in Acute Myeloid Leukemia (AML) Patients with Normal Cytogenetics: Expression Levels and Impact On Clinical Outcome. A Study of the AMLSG.. <i>Blood</i> , 2009, 114, 1600-1600.	0.6	1
498	Shift to a New Donor Does Not Improve the Outcome After Second Allogeneic Stem Cell Transplantation (alloSCT) in Acute Leukemia Relapse After a First Allosct – a Risk Factor Analysis by the German Stem Cell Registry (DRST).. <i>Blood</i> , 2009, 114, 3328-3328.	0.6	1
499	MN1 Inhibits Myeloid Differentiation by Transcriptional Repression of EGR2. <i>Blood</i> , 2010, 116, 229-229.	0.6	1
500	An Intergroup Randomised Trial of Standard Intensity Versus Reduced Intensity TBI-Based Conditioning In Patients with Acute Myeloid Leukemia in First Complete Remission. <i>Blood</i> , 2011, 118, 157-157.	0.6	1
501	Deletion or Inhibition of Fc Gamma Receptor IIb (CD32) Prevents the Memory B Cell Response to Factor VIII in a Hemophilia A Mouse Model. <i>Blood</i> , 2011, 118, 204-204.	0.6	1
502	ASXL1 Mutations Predict for Resistance to Chemotherapy and Inferior Outcome in Younger Adult Patients with Acute Myeloid Leukemia (AML): A Study of the German-Austrian AMLSG. <i>Blood</i> , 2011, 118, 412-412.	0.6	1
503	DNMT3A mutations Predict for Inferior Outcome in NPM1-Wildtype and Molecular Unfavorable Cytogenetically-Normal Acute Myeloid Leukemia: A Study of the German-Austrian AMLSG. <i>Blood</i> , 2011, 118, 415-415.	0.6	1
504	Matched Pair Analysis of Cryopreserved Versus Fresh Allogeneic Peripheral Blood Stem Cell Transplantation. <i>Blood</i> , 2011, 118, 4529-4529.	0.6	1

#	ARTICLE	IF	CITATIONS
505	Prognostic Impact of Splicing Factor Mutations in Patients with Myelofibrosis Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2014, 124, 3171-3171.	0.6	1
506	The Metabolite R-2-Hydroxyglutarate (R2HG) Collaborates with HoxA9 to Induce Monocytic Leukemia. <i>Blood</i> , 2014, 124, 366-366.	0.6	1
507	Casein Kinase 1A1 (CSNK1A1) Is Recurrently Mutated in MDS Patients with Deletion of Chromosome 5q. <i>Blood</i> , 2014, 124, 4643-4643.	0.6	1
508	Clonal Evolution in NPM1 Mutated Acute Myeloid Leukemia (AML). <i>Blood</i> , 2015, 126, 1381-1381.	0.6	1
509	Molecular Characterization of Relapsed Core-Binding Factor (CBF) Acute Myeloid Leukemia (AML). <i>Blood</i> , 2015, 126, 2586-2586.	0.6	1
510	Application of a Short Tandem Repeat Based PCR Assay for Chronological Monitoring of Myelodysplastic Syndrome (MDS) Patients with Deletion of Chromosome 5q Following Lenalidomide Treatment. <i>Blood</i> , 2015, 126, 2891-2891.	0.6	1
511	Incidence and Prognostic Relevance of ASXL2 Mutations in Adult CBF-AML with t(8;21)(q22;q22): A Study of the German-Austrian AML Study Group (AMLSG). <i>Blood</i> , 2015, 126, 3818-3818.	0.6	1
512	Allogeneic Hematopoietic Stem Cell Transplantation for Secondary Acute Myeloid Leukemia- a Report from the Acute Leukemia Working Party of the EBMT. <i>Blood</i> , 2015, 126, 63-63.	0.6	1
513	Personally Tailored Risk Prediction of AML Based on Comprehensive Genomic and Clinical Data. <i>Blood</i> , 2015, 126, 85-85.	0.6	1
514	An EBMT Prospective Non-Interventional Study of Outcomes and Toxicity of Allogeneic Stem Cell Transplantation in Chronic Myeloid Leukemia Patients Previously Treated with Second Generation Tyrosine Kinase Inhibitors. <i>Blood</i> , 2016, 128, 628-628.	0.6	1
515	Active surveillance (AS) in the management of patients (pts) with metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2016, 34, e16070-e16070.	0.8	1
516	Priming with Granulocyte Colony-Stimulating Factor (G-CSF) Has No Impact on Treatment Outcome but Impairs Mobilization of Peripheral Blood Stem Cells (PBSC) in Elderly Patients with Acute Myeloid Leukemia: Results of a Randomized Oligocenter Trial.. <i>Blood</i> , 2004, 104, 867-867.	0.6	1
517	Detection of RAS, KIT and FLT3 Gene Mutations in t(8;21)-Positive Acute Myeloid Leukemia (AML): Evaluation of the Clinical Relevance.. <i>Blood</i> , 2006, 108, 2301-2301.	0.6	1
518	All-Trans Retinoic Acid and Gemtuzumab Ozogamicin as Adjunct To Salvage Therapy in Primary Refractory Acute Myeloid Leukemia: Results of Consecutive Phase II Studies of the AMLSG.. <i>Blood</i> , 2006, 108, 1949-1949.	0.6	1
519	RAS, KIT and FLT3 Gene Mutations in inv(16)/t(16;16)-Positive Acute Myeloid Leukemia (AML): Incidence and Relevance on Clinical Outcome.. <i>Blood</i> , 2006, 108, 2303-2303.	0.6	1
520	All-Trans Retinoic Acid and Gemtuzumab Ozogamicin as Adjunct to High-Dose Cytarabine-Based Salvage Therapy in Primary Refractory Acute Myeloid Leukemia: Results of AMLSG 05-04 Trial.. <i>Blood</i> , 2007, 110, 1837-1837.	0.6	1
521	Prognostic Factors in Adult Patients up to 60 Years with AML and Translocations of Chromosome 11q23: Individual Patient Data Based Analysis of the German AML-Intergroup.. <i>Blood</i> , 2007, 110, 759-759.	0.6	1
522	Lineage-Specific Regulation of miRNA-Expression by the BCR-ABL Oncogene.. <i>Blood</i> , 2008, 112, 1084-1084.	0.6	1

#	ARTICLE	IF	CITATIONS
523	Prospective Evaluation of An Agvhd-Specific Proteomic Pattern in More Than 340 Patients.. Blood, 2009, 114, 347-347.	0.6	1
524	High EVI1 Expression Predicts Outcome in Younger Adult (15 to 60 years) Patients with Acute Myeloid Leukemia and Is Associated with Distinctive Cytogenetic Subgroups.. Blood, 2009, 114, 582-582.	0.6	1
525	Mutations in the Fms-Related Tyrosine Kinase 3 (FLT3) Gene Independently Predict Poor Outcome in Acute Myeloid Leukemia (AML) with t(8;21): A Study of the German-Austrian AML Study Group (AMLSG).. Blood, 2009, 114, 825-825.	0.6	1
526	Identification of Clinically Relevant Predictive MRD Checkpoints in AML Patients with NPM1 Mutations: A Study of the AML Study Group (AMLSG).. Blood, 2009, 114, 1586-1586.	0.6	1
527	FLT3-ITD and Age Are the Major Prognostic Factors In Relapsed AML with Normal Karyotype. Blood, 2010, 116, 1719-1719.	0.6	1
528	NF1 Alterations Are Common In AML with Complex Karyotype and Correlate with Specific Genomic Imbalances. Blood, 2010, 116, 4179-4179.	0.6	1
529	Genetic Profile of Acute Erythroid Leukemia. Blood, 2016, 128, 40-40.	0.6	1
530	Frequency and Clinical Characteristics Associated with Putative CAR Targets ADGRE2, CCR1, CD70, and LILRB2 in Acute Myeloid Leukemia. Blood, 2018, 132, 5259-5259.	0.6	1
531	Ibrutinib for Relapsed Mantle Cell Lymphoma after Standard First Line Therapy and ASCT Is Efficacious but Does Not Overcome the Impact of POD24 - a Retrospective Study from the LWP-EBMT. Blood, 2019, 134, 701-701.	0.6	1
532	Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Patients with Therapy-Related Myeloid Neoplasm: A Study from the Chronic Malignancies Working Party of the EBMT. Blood, 2019, 134, 45-45.	0.6	1
533	Midostaurin Plus Intensive Chemotherapy for Younger and Older Patients with Acute Myeloid Leukemia and FLT3 Internal Tandem Duplications. Blood, 2021, 138, 692-692.	0.6	1
534	Isocitrate Dehydrogenase (IDH) 1 and 2 Mutation Is an Independent Predictor of Better Outcome in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: A Study of the ALWP of EBMT. Blood, 2021, 138, 2920-2920.	0.6	1
535	Activity of Decitabine (DAC) Combined with All-Trans Retinoic Acid (ATRA) in Oligoblastic AML: Subgroup Analysis of a Randomized 2x2 Phase II Trial. Blood, 2020, 136, 9-10.	0.6	1
536	AML1/ETO inhibits AML1/CCAAT-enhancer binding protein-alpha mediated activation of the CD11c promoter and represses CD11c expression in HL60 cells. Haematologica, 2003, 88, 956-8.	1.7	1
537	Increased late non-cardiac non-relapse mortality in patients with atrial fibrillation diagnosed during hospital stay for allogeneic stem cell transplantation. Transplantation and Cellular Therapy, 2022, , .	0.6	1
538	Stem Cell Mobilization in Normal Donors. Stem Cells and Development, 1998, 7, 5-7.	1.0	0
539	Bendamustine. Drugs, 2001, 61, 639-640.	4.9	0
540	New Editor-in-Chief. Annals of Hematology, 2003, 82, 206-206.	0.8	0

#	ARTICLE	IF	CITATIONS
541	Hematopoietic Growth Factorsâ€™ Present Status and Future Development. <i>Seminars in Hematology</i> , 2007, 44, 131-132.	1.8	0
542	A database of naturally occurring human urinary peptides and proteins for use in clinical applications. <i>Nature Precedings</i> , 2007, , .	0.1	0
543	Addition of in-vitro generated endothelial microparticles to von-Willebrand plasma improves primary and secondary hemostasis. <i>Thrombosis Research</i> , 2014, 133, 445-450.	0.8	0
544	Who Is the Best Haematopoietic Stem Cell Donor for a Male Patient with Acute Leukaemia?. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, S42.	2.0	0
545	MP475 OXALIPLATIN PHARMACOKINETICS ON HEMODIALYSIS IN A PATIENT WITH DIFFUSE LARGE B-CELL LYMPHOMA. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, i499-i499.	0.4	0
546	476. No GVHD, but Human Inflammatory â€™Cytokine Stormâ€™ and Mouse Macrophage Activation Upon Accelerated Development of Human CD4+ Effector Memory T Cells in Long-Term Humanized Mice. <i>Molecular Therapy</i> , 2016, 24, S188.	3.7	0
547	Accurate quantification of chromosomal lesions via short tandem repeat analysis using minimal amounts of DNA. <i>Journal of Medical Genetics</i> , 2017, 54, 640-650.	1.5	0
548	Outcome of Third Salvage Autologous Stem Cell Transplantation in Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e124.	0.2	0
549	The application of an integrated clinical, cytogenetic, and molecular risk stratification for acute myeloid leukemia patients using a central laboratory in a Brazilian multicentric study. <i>Blood Advances</i> , 2017, 1, 86-89.	2.5	0
550	Outcome of Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Acute Myeloid Leukemia over 70 Years of Age: On Behalf of the Acute Leukemia Working Party of the EBMT. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S232-S233.	2.0	0
551	Comparison of Transplant Outcomes in Patients with Acute Lymphoblastic Leukemia after Haploidentical Transplant with Post-Transplant Cyclophosphamide or Matched Unrelated Donor Transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S58-S59.	2.0	0
552	Donor-derived IL-17A and IL-17F deficiency triggers Th1 allo-responses and increases gut leakage during acute GVHD. <i>PLoS ONE</i> , 2020, 15, e0231222.	1.1	0
553	What can Heraclitus tell us about AML?. <i>Blood</i> , 2021, 137, 2719-2720.	0.6	0
554	Is allogeneic transplantation the preferred therapy for older patients with acute myeloid leukemia?. <i>Haematologica</i> , 2021, , .	1.7	0
555	Drug-Response Signature Predicts Outcome in Adult Acute Myeloid Leukemia and Associates Poor Response with Molecular Characteristics of Hematopoietic Stem Cells.. <i>Blood</i> , 2004, 104, 2024-2024.	0.6	0
556	Analysis of Vector Integration with LM-PCR after Retroviral HSV-Tk/Î”LNGFR Gene Transfer.. <i>Blood</i> , 2004, 104, 1752-1752.	0.6	0
557	Prospective Evaluation of a GvHD-Specific Proteom Pattern.. <i>Blood</i> , 2004, 104, 728-728.	0.6	0
558	Thromboelastometry in Patients Receiving Platelet Transfusion after Chemotherapy.. <i>Blood</i> , 2004, 104, 3630-3630.	0.6	0

#	ARTICLE	IF	CITATIONS
559	Treatment of Del(5q) Myelodysplastic Syndrome with All-Trans-Retinoic Acid and Tocopherol-Î±.. Blood, 2004, 104, 4729-4729.	0.6	0
560	Acute Myeloid Leukemia with Deletion 9q Is Associated with CEBPA Loss-of-Function Mutations.. Blood, 2004, 104, 2896-2896.	0.6	0
561	Differential Sensitivity of Normal and CML-Derived CD34+ Cells to Inhibition of SHP-2 Gene Expression by RNA Interference (RNAi).. Blood, 2004, 104, 2778-2778.	0.6	0
562	Decrease of Malignant Potential of t(8;21) Positive Cells after Stable Expression of RUNX-CBFA2T1-Specific Small Interfering RNA.. Blood, 2004, 104, 4274-4274.	0.6	0
563	Marrow Fibrosis in Myelodysplastic Syndromes - Its Significance in the Context of the WHO Classification of Disease and the International Prognostic Scoring System.. Blood, 2004, 104, 1446-1446.	0.6	0
564	Targeting RAS Signaling in Multiple Myeloma (MM): Synergistic Inhibition by Co-Treatment with the MEK Inhibitor U0126 and Prenylation Inhibitors.. Blood, 2004, 104, 3398-3398.	0.6	0
565	MN1 Expression Predicts Prognosis of Acute Myeloid Leukemia with Normal Cytogenetics.. Blood, 2005, 106, 2351-2351.	0.6	0
566	Isolation of Cytomegalovirus (CMV) Specific T-Cells from Sersopositive Donors: A Possible Tool for CMV-Prophylaxis.. Blood, 2005, 106, 3037-3037.	0.6	0
567	Prenylation Inhibitors Block IL-6 and IGF-1 Dependent Activation of RAS Signaling in Multiple Myeloma Cells.. Blood, 2005, 106, 3373-3373.	0.6	0
568	Pooled Data Analysis of Acute Myeloid Leukemia Patients <= 60 Years with Trisomy 8 Treated within the Studies of the German Acute Myeloid Leukemia Intergroup.. Blood, 2005, 106, 2374-2374.	0.6	0
569	Allogeneic Transplantation from an HLA-Matched Family Donor in First Complete Remission of Acute Myeloid Leukemia Had an Adverse Impact on Quality of Life in Patients Followed for at Least Five Years after Treatment: A Survey of the German AML Intergroup on 525 Patients.. Blood, 2005, 106, 747-747.	0.6	0
570	Prospective Evaluation of Graft-Versus-Host Disease-Specific Proteomics Pattern in Patients after Allogeneic Stem Cell Transplantation.. Blood, 2005, 106, 3093-3093.	0.6	0
571	All-Trans Retinoic Acid and Gemtuzumab Ozogamicin as Adjunct To Salvage Therapy in Primary Refractory Acute Myeloid Leukemia: Results of Consecutive Phase II Studies of the AMLSG.. Blood, 2005, 106, 1849-1849.	0.6	0
572	Atypical Presentations of EBV Reactivation and EBV-Associated PTLD Post-HSCT: Implication for Routine EBV Surveillance after Allogeneic HSCT?.. Blood, 2005, 106, 5364-5364.	0.6	0
573	Regulation of T Cell Homeostasis and Cell Cycling in Patients with Acute Myeloid Leukemia.. Blood, 2005, 106, 2767-2767.	0.6	0
574	Reduced Binding of C/EBPÎ± to Myeloid Specific Promoters with Altered Gene Expression in the Presence of PML/RARÎ±.. Blood, 2005, 106, 2999-2999.	0.6	0
575	Emerging Marrow Fibrosis Is an Early Indicator of Imatinib Failure and Shortened Survival Time in CML Independent of Hematologic, Cytogenetic and Molecular Response.. Blood, 2005, 106, 1106-1106.	0.6	0
576	Comparison of HLA-Identical Sibling Hematopoietic Stem Cell Transplant (HCT) Versus Chemotherapy as Postremission Therapy in t(8;21) Acute Myeloid Leukemia (AML).. Blood, 2005, 106, 1138-1138.	0.6	0

#	ARTICLE	IF	CITATIONS
577	Prospective Randomized Comparison of High Dose AraC and Autologous Peripheral Blood Stem Cell Transplantation as Late Consolidation for Patients ≥ 60 Years with Standard Risk AML.. Blood, 2005, 106, 151-151.	0.6	0
578	Impact of Different Postremission Strategies in Younger Adults with Acute Myeloid Leukemia and Normal Karyotype Exhibiting a CEBPA Mutation.. Blood, 2005, 106, 2352-2352.	0.6	0
579	Prospective Randomized Comparison of High Dose AraC and AutoPBSCT as Late Consolidation for Patients ≥ 60 Years with Standard Risk AML: Final Results of the AML SHG-Hannover 01/99 Trial.. Blood, 2006, 108, 607-607.	0.6	0
580	Leukemogenic Cascade Induced by a Constitutively Active Neurotrophin Receptor, $\hat{1}^{\text{trkA}}$.. Blood, 2006, 108, 1442-1442.	0.6	0
581	Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients - A Single Center Study.. Blood, 2006, 108, 3030-3030.	0.6	0
582	Unrelated Hematopoietic Blood Stem Cell Transplantation in Patients with Acute Myelogenous Leukemia (AML) in First Remission.. Blood, 2006, 108, 3141-3141.	0.6	0
583	Characterization of a Novel R-RAS Mutation Cloned from Primary AML Cells.. Blood, 2006, 108, 1439-1439.	0.6	0
584	Prognostic Impact of BAALC Expression in the Context of Other Molecular Markers in Cytogenetically Normal Acute Myeloid Leukemia.. Blood, 2007, 110, 3485-3485.	0.6	0
585	An Ex Vivo Perfusion Model To Study the Treatment of Thrombotic Microangiopathy during Pig-to-Human Xenogenic Kidney Transplantation.. Blood, 2007, 110, 3190-3190.	0.6	0
586	FLAMSA Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation in High Risk Myeloid Malignancies Is Also Feasible with Partially Mismatched Donors.. Blood, 2007, 110, 3068-3068.	0.6	0
587	Impact of Pegfilgrastim and Dosing Schedule of Cytarabine on Hematological Reconstitution Times, Incidences of Severe Infection and Duration of Hospitalization after Consolidation Therapy with High-Dose Cytarabine in Acute Myeloid Leukaemia - Interim Results from AMLSG 07-04 Trial.. Blood, 2007, 110, 1836-1836.	0.6	0
588	Specific MiRNA Silencing by Lentivirus Mediated Antagomir Expression in Chronic Myeloid Leukemia (CML) Cells.. Blood, 2007, 110, 1017-1017.	0.6	0
589	Potential of Topoisomerase II Inhibitor-Mediated Myeloid Leukemia Cell Kill by Farnesyltransferase Inhibitor L-744,832.. Blood, 2007, 110, 3479-3479.	0.6	0
590	Neurotrophin Receptors and Ligands Are Highly Expressed in Acute Leukemia and Promote Leukemogenesis.. Blood, 2007, 110, 696-696.	0.6	0
591	The Impact of Therapy-Related and Secondary AML in Relation to Karyotype and Molecular Markers: A Study of the AMLSG.. Blood, 2007, 110, 881-881.	0.6	0
592	Prognostic Factors in Patients Receiving An Allogeneic Stem Cell Transplantation for Relapsed AML. Results of the Prospective AML 295 and 01/99 Studies. Blood, 2008, 112, 344-344.	0.6	0
593	Circulating Angiopoietin-2 Predicts Time to Relapse after Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia.. Blood, 2008, 112, 3259-3259.	0.6	0
594	Trans-Atlantic Consensus on the Medical Management of Radiation Accident Victims. Blood, 2008, 112, 2361-2361.	0.6	0

#	ARTICLE	IF	CITATIONS
595	Prognostic Implication of Insertion of FLT3 Internal Tandem Duplication in the BETA-1-Sheet of the Tyrosine Kinase Domain-1. Blood, 2008, 112, 2514-2514.	0.6	0
596	Treatment-Related AML Is An Independent Adverse Prognostic Factor for Relapse-Free and Overall Survival. An Analysis of 2,868 Adult Patients with Newly Diagnosed AML Enrolled On Seven AMLSG Treatment Trials.. Blood, 2009, 114, 578-578.	0.6	0
597	Long Term Results of Allogeneic Hematopoietic Cell Transplantation in Elderly Patients.. Blood, 2009, 114, 3388-3388.	0.6	0
598	Secondary AML After a History of Myelodysplastic Syndrome Is An Independent Adverse Prognostic Factor for Achievement of Complete Remission, Relapse-Free and Overall Survival. An Analysis of 2,819 Adult Patients with Newly Diagnosed AML Enrolled On Seven AMLSG Treatment Trials.. Blood, 2009, 114, 2621-2621.	0.6	0
599	Human Development Index Correlates with Rates and Influences Outcome of Hematopoietic Stem Cell Transplantation for Patients with Acute Leukemia.. Blood, 2009, 114, 1193-1193.	0.6	0
600	Differential Expression of Mirna* Species in Cancer and the Contribution of MiR-223* to the Development of Acute Myeloid Leukemia.. Blood, 2009, 114, 2960-2960.	0.6	0
601	Favorable Prognostic Impact of WT1 SNP rs16754 in Cytogenetically Normal AML Independent of MN1, BAALC, and ERG Expression.. Blood, 2009, 114, 1622-1622.	0.6	0
602	A Novel Proteomic Approach to Define Leukemia Cell Resistance to Farnesyltransferase Inhibitors.. Blood, 2009, 114, 3761-3761.	0.6	0
603	Mobilized Peripheral Blood Stem Cells (PBSC) Compared with Bone Marrow (BM) as the Stem Cell Source for Unrelated Donor Allogeneic Transplantation with Reduced Intensity Conditioning (RIC-alloSCT) in Patients with Acute Myeloid Leukemia (AML) in Complete Remission (CR): a Retrospective Analysis From the ALWP of EBMT.. Blood, 2009, 114, 527-527.	0.6	0
604	Gene Expression Analysis of Independent Data Sets Identifies HBG1 to Be Associated with Outcome in Cytogenetically Normal AML.. Blood, 2009, 114, 2613-2613.	0.6	0
605	Prospective Evaluation of Proteomic Screening with An Agvhd-Specific Proteomic Pattern MS-17.. Blood, 2009, 114, 2246-2246.	0.6	0
606	Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia with Normal Karyotype: A Risk Factor Analysis in 247 Patients, Based On Molecular Markers and Stage at Transplantation.. Blood, 2009, 114, 1209-1209.	0.6	0
607	Proteomic Screening Applied to the Diagnosis of Chronic Graft-Versus-Host-Disease.. Blood, 2009, 114, 1164-1164.	0.6	0
608	Functional Role of BAALC In Leukemogenesis. Blood, 2010, 116, 4194-4194.	0.6	0
609	Enforced Expression of Mir-125b Blocks Granulocytic Differentiation by Simultaneous Repression of Multiple Targets.. Blood, 2010, 116, 1554-1554.	0.6	0
610	Is Longer MDS Duration Prior to Non-Intensive AML Treatment a Favorable Prognostic Factor? Results of the 00331 Multicenter Phase II Decitabine Trial. Blood, 2010, 116, 2185-2185.	0.6	0
611	Prognostic Importance of Duration of MDS Prior to Randomization Between Decitabine (DAC) Vs. Best Supportive Care (BSC) In Elderly IPSS Intermediate-2 and High Risk MDS Patients: Results of the 06011 EORTC-GMDSSG Phase III Trial. Blood, 2010, 116, 4024-4024.	0.6	0
612	Tregs In Graft-Versus-Host Disease: A Task Force In Trouble?.. Blood, 2010, 116, 3748-3748.	0.6	0

#	ARTICLE	IF	CITATIONS
613	High-Resolution Genomic Profiling of Adult and Pediatric Core Binding Factor Acute Myeloid Leukemia Reveals New Recurrent Genomic Aberrations. <i>Blood</i> , 2010, 116, 849-849.	0.6	0
614	Acute Myeloid Leukemia (AML): Prospective Comparison of Different Treatments with a Common Standard Treatment - A Study by the German AML Intergroup. <i>Blood</i> , 2010, 116, 2175-2175.	0.6	0
615	Virus-Associated Hemophagocytic Syndrome Contributes to Fatal Outcome In Critical Ill Patients with 2009 Influenza A (H1N1) Infection.. <i>Blood</i> , 2010, 116, 3795-3795.	0.6	0
616	Prospective Evaluation of Immunophenotype In Correlation to Genotype In Previously Untreated Adult Patients with Acute Myeloid Leukemia In the Context of the WHO Classification. <i>Blood</i> , 2010, 116, 1693-1693.	0.6	0
617	Modulation of Anthracycline-Induced Cytotoxicity by Targeting the Prenylated Prenylome in Myeloid Leukemia Cells. <i>Blood</i> , 2011, 118, 1418-1418.	0.6	0
618	Regulatory T Cells of G-CSF Mobilized Stem Cell Donors Qualify for Clinical Applications,. <i>Blood</i> , 2011, 118, 4055-4055.	0.6	0
619	Endothelial Microparticles Improve Primary and Secondary Hemostasis in Patients with Von-Willebrand Disease. <i>Blood</i> , 2011, 118, 2287-2287.	0.6	0
620	The Role of MSI2 Expression Levels on Outcome of MDS and AML Patients. <i>Blood</i> , 2011, 118, 1734-1734.	0.6	0
621	ID1 Expression Correlates with CEBPA Mutational Status and Is Not An Independent Risk Factor in Cytogenetically Normal AML,. <i>Blood</i> , 2011, 118, 3554-3554.	0.6	0
622	Prevalence and Clinical Effect of TET2 Mutations in Cytogenetically Normal Acute Myeloid Leukemia (CN-AML). <i>Blood</i> , 2011, 118, 1448-1448.	0.6	0
623	Assessment of Clonal Evolution in 42 AML with NPM1 Mutations by Molecular Characterization of Paired Diagnosis and Relapse Samples. <i>Blood</i> , 2011, 118, 237-237.	0.6	0
624	Next Generation Sequencing for Minimal Residual Disease Monitoring in AML Patients with FLT3-ITD,. <i>Blood</i> , 2011, 118, 3548-3548.	0.6	0
625	Function of STAT5 Isoforms in Bcr-Abl Positive Cells. <i>Blood</i> , 2011, 118, 1313-1313.	0.6	0
626	FLT3-ITD-Associated Accumulation of Dendritic Cell Precursors, Depletion of Mature Dendritic Cells and Abnormal Cytokine Production in Acute Myeloid Leukemia: Analyses At Diagnosis, Remission and Relapse. <i>Blood</i> , 2011, 118, 2525-2525.	0.6	0
627	Monocytes Induced to Differentiate Into Dendritic Cells After Overnight Transduction with Lentiviral Vectors Co-Expressing GM-CSF/ IL-4 and a Truncated Form of WT1: Preclinical Validation for Immunotherapy of High Risk Leukemia Patients After Allo-SCT. <i>Blood</i> , 2011, 118, 2981-2981.	0.6	0
628	Overall Outcome of Relapsed Acute Lymphoblastic Leukemia Can Be Improved by Stem Cell Transplantation and Early Treatment in Stage of Molecular Relapse. <i>Blood</i> , 2011, 118, 250-250.	0.6	0
629	Role of IL-15 in the Stimulation of Human CD8+ CMV-Reactive Human T Cells in a Hu-PBL Mouse Model Preconditioned with Self-Differentiated Human Dendritic Cells Programmed with Lentiviral Vectors. <i>Blood</i> , 2011, 118, 2966-2966.	0.6	0
630	Prognostic Significance and Target Potential of Axl in Acute Myeloid Leukemia. <i>Blood</i> , 2011, 118, 940-940.	0.6	0

#	ARTICLE	IF	CITATIONS
631	Persistence of Recipient-Derived Antiviral T cells Severely Influence Donor Chimerism Post Allogeneic HSCT,. Blood, 2011, 118, 3240-3240.	0.6	0
632	Deregulated Expression of EVI1 Defines a Poor Prognostic Subset of MLL-Rearranged Acute Myeloid Leukemias. Blood, 2011, 118, 1441-1441.	0.6	0
633	Hematologic Responses in Patients with Aplastic Anemia Treated with Deferasirox: A Post-Hoc Analysis From the EPIC Study. Blood, 2011, 118, 1344-1344.	0.6	0
634	Clofarabine Containing Conditioning Regimen for Allo-SCT in AML/ALL Patients: A Survey From the Acute Leukemia Working Party of EBMT. Blood, 2011, 118, 3004-3004.	0.6	0
635	Proteomic Pattern-Based Risk Stratification of Outcome Shows Significant Higher Accuracy Compared to HCT-CI in Patients with AML and MDS,. Blood, 2011, 118, 4128-4128.	0.6	0
636	Sequential Chemotherapy Followed by Reduced Intensity Conditioning and Allogeneic Stem Cell Transplantation (allo-SCT) in Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML): A Survey From the Acute Leukemia Working Party of EBMT. Blood, 2012, 120, 2025-2025.	0.6	0
637	Routes of Clonal Evolution Into Complex Karyotypes in Myelodysplastic Syndrome Patients with Del(5q). Blood, 2012, 120, 522-522.	0.6	0
638	Genome Wide DNA Methylation Analysis of Patients with Myelodysplastic Syndrome and Isolated Deletion (5q) Reveals Characteristic Methylation Profiles in Low and Intermediate-1 Risk Groups. Blood, 2012, 120, 3801-3801.	0.6	0
639	Aberrant Expression of the MLL5, BAALC, ID1, and WT1 Genes Is Associated with Higher Induction Mortality and Poorer Overall Survival in Acute Promyelocytic Leukemia Patients Treated with ATRA and Anthracycline-Based Chemotherapy: An International Consortium On Acute Promyelocytic Leukemia Study. Blood, 2012, 120, 1407-1407.	0.6	0
640	Prognostic Factors Identified Via a Cox Proportional Hazard Cure Model Explain Survival Differences After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Chronic Myeloid Leukemia (CML) Between Two Consecutive Patient Cohorts. Blood, 2012, 120, 3748-3748.	0.6	0
641	Impact of ASXL1 Mutations On Outcome After Reduced Intensity Allograft in Patients with Myelofibrosis. Blood, 2012, 120, 1740-1740.	0.6	0
642	Investigation of Urine/Plasma Biomarkers to Predict Tolerance and Graft-Versus-Host Disease Post Allogeneic Stem Cell Transplantation.. Blood, 2012, 120, 3049-3049.	0.6	0
643	High-Dose Therapy and Autologous Stem Cell Transplantation for Extra-Nodal NK/T Lymphoma in Western Patients; A Study From the European Group for Blood and Marrow Transplantation (EBMT).. Blood, 2012, 120, 3148-3148.	0.6	0
644	Decitabine (DAC) Vs. Best Supportive Care in Elderly Patients with Intermediate- and High-Risk MDS with or without Monosomal Karyotypes: Results of the EORTC-LG/German MDS-SG Randomized Phase III Trial 06011.. Blood, 2012, 120, 2804-2804.	0.6	0
645	Prognostic Impact of Mutant to Wild-Type Ratio and Insertion Site in Acute Myeloid Leukemia with FLT3 Internal Tandem Duplication. Blood, 2012, 120, 785-785.	0.6	0
646	Mutated IDH1 Has 2-Hydroxyglutarate-Independent Functions in Leukemogenesis. Blood, 2012, 120, 770-770.	0.6	0
647	Prognostic Impact of Recipient and Donor CMV Serostatus in Acute Leukemia Patients After Allogeneic Stem Cell Transplantation At the Era of Preemptive Therapy.. Blood, 2012, 120, 3110-3110.	0.6	0
648	Prognostic value of free testosterone (FT) levels during salvage chemotherapy with carboplatin plus weekly docetaxel in metastatic castration- and docetaxel-resistant prostate cancer (mDRPC).. Journal of Clinical Oncology, 2013, 31, 152-152.	0.8	0

#	ARTICLE	IF	CITATIONS
649	Effectiveness of abiraterone as salvage therapy in patients with docetaxel- and castration-resistant prostate cancer (mDCPC) that progressed during second-line chemotherapy with carboplatin plus weekly docetaxel (DC).. Journal of Clinical Oncology, 2013, 31, e16064-e16064.	0.8	0
650	Genetic Characterization Of Aplastic Anemia Patients By Targeted Sequencing. Blood, 2013, 122, 2470-2470.	0.6	0
651	Prognostic Impact Of a Newly Defined Structurally Complex Karyotype In Patients With AML and MDS After Allogeneic Stem Cell Transplantation. Blood, 2013, 122, 3362-3362.	0.6	0
652	Analysis Of Micro-RNA-142 Mutations In a Cohort Of 944 Patients With MDS and AML. Blood, 2013, 122, 2804-2804.	0.6	0
653	Minimal Residual Disease (MRD) Monitoring in NPM1 Mutated Acute Myeloid Leukemia (AML): Impact of Concurrent FLT3-ITD and DNMT3A Mutations on MRD Kinetics and Clinical Outcome. Blood, 2013, 122, 2555-2555.	0.6	0
654	Impact Of The Pretreatment Characteristics As Well As Cyto- and Molecular-Genetic Profile On Outcome After Relapse In Acute Myeloid Leukemia. Blood, 2013, 122, 830-830.	0.6	0
655	Treatment Results In Acute Myeloid Leukemia Over a Time Period Of 20 Years: Analysis Of The German-Austrian Acute Myeloid Leukemia Study Group (AMLSC). Blood, 2013, 122, 3878-3878.	0.6	0
656	An Adapted Gating Strategy Integrating a Myelomonocytic Window Is Necessary For Correct Flow Cytometric Diagnosis In a Large Proportion Of AML With Mutated NPM1. Blood, 2013, 122, 2593-2593.	0.6	0
657	Prognostic Value Of Plasma Biomarkers Compared To Urinary Proteome Patterns. Blood, 2013, 122, 4593-4593.	0.6	0
658	Clinical Impact of GATA2 Mutations in Acute Myeloid Leukemia Patients Harboring CEBPA Mutations: A Study of the AML Study Group (AMLSC). Blood, 2013, 122, 1332-1332.	0.6	0
659	Outcomes In RBC Transfusion-Dependent Patients (Pts) With Low-/Intermediate (Int)-1-Risk Myelodysplastic Syndromes (MDS) With Isolated Deletion 5q Treated With Lenalidomide (LEN): A Subset Analysis From The MDS-004 Study. Blood, 2013, 122, 2753-2753.	0.6	0
660	The Clinical and Prognostic Influence Of Mutations In The Cohesin Complex In Acute Myeloid Leukemia. Blood, 2013, 122, 1314-1314.	0.6	0
661	Mirâ¼17-92 Identifies BCL2 As a Therapeutic Target In BCR-ABL Positive B-Lineage Acute Lymphoblastic Leukemia. Blood, 2013, 122, 835-835.	0.6	0
662	Prognostic Impact Of MLL5 transcript Levels On Outcome Of Patients With Acute Promyelocytic Leukemia Treated With All-Trans Retinoic Acid and Anthracycline-Based Chemotherapy: An International Consortium On Acute Promyelocytic Leukemia Study. Blood, 2013, 122, 2586-2586.	0.6	0
663	TP53 Mutations Detected By Next-Generation Deep-Sequencing In Patients With Myelodysplastic Syndrome and Isolated Deletion (5q): Results From a German Multicenter Trial. Blood, 2013, 122, 2759-2759.	0.6	0
664	Graft Versus Leukemia With Little Graft Versus Host Disease? Long Term Follow-Up Of a Study Using Transduced Donor T-Cells For Donor Leukocyte Transfusion. Blood, 2013, 122, 4207-4207.	0.6	0
665	Late onset of bone metastases as a prognostic parameter in metastatic renal cell cancer (mRCC): A single-center experience in 82 mRCC patients treated with sunitinib.. Journal of Clinical Oncology, 2014, 32, 523-523.	0.8	0
666	Prognostic value of free testosterone (FT) levels during salvage chemotherapy with carboplatin plus weekly docetaxel in metastatic castration- and docetaxel-resistant prostate cancer (mDRPC).. Journal of Clinical Oncology, 2014, 32, 5084-5084.	0.8	0

#	ARTICLE	IF	CITATIONS
667	Impact of Donor Type on Outcome after Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia Patients: Analysis of the German-Austrian Acute Myeloid Leukemia Study Group (AMLSCG). Blood, 2014, 124, 1254-1254.	0.6	0
668	Cost-Effectiveness Analysis of Arsenic Trioxide in Combination with All-Trans Retinoic Acid in Acute Promyelocytic Leukemia with Pretreatment White Blood Counts $\leq 10 \times 10^9/L$. Blood, 2014, 124, 2636-2636.	0.6	0
669	Expression of the ETS Transcription Factor GABP1 Is Correlated to BCR-ABL/ABL ratio in Human CML and Mediates Imatinib Sensitivity. Blood, 2014, 124, 1787-1787.	0.6	0
670	Allogeneic Stem Cell Transplantation in Myelodysplastic Syndrome; A More Favorable Outcome after Fludarabine and Treosulfan Conditioning, a Survey on Behalf of the Chronic Malignancies Working Party of the EBMT. Blood, 2014, 124, 1216-1216.	0.6	0
671	Clinical Impact of TP53 Mutations in Patients with MDS and Isolated Deletion 5(q) Treated with Lenalidomid: Results from the German Prospective Le-Mon-5 Trial. Blood, 2014, 124, 1920-1920.	0.6	0
672	High-Throughput Drug Screening Identifies Pyrimethamine As a Potent and Selective Inhibitor of Acute Myeloid Leukemia. Blood, 2014, 124, 2304-2304.	0.6	0
673	Characteristics and Prognosis of AML Patients with or without a History of Clonal Hematopoiesis. Blood, 2015, 126, 224-224.	0.6	0
674	Changes of the Niche of Erythropoiesis Appear to Contribute to Severe Transfusion-Dependent Anemia in a Significant Proportion of Patients with Myelodysplastic Syndromes. Blood, 2015, 126, 4114-4114.	0.6	0
675	Major Route Additional Chromosomal Aberrations (ACA) Precede Increase of Blasts in CML: An Analysis of the German CML-Studies III and IIIA. Blood, 2015, 126, 1581-1581.	0.6	0
676	Sequential Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with High-Risk AML in Complete Remission: A Survey from the ALWP of the EBMT. Blood, 2015, 126, 3105-3105.	0.6	0
677	Comparison of Matched-Sibling Donors Versus Unrelated Donors in Allogeneic Stem Cell Transplantation (allo-SCT) for Primary Refractory Acute Myeloid Leukemia (PRF AML): A Report of 1041 Patients from the Acute Leukemia Working Party of the EBMT. Blood, 2015, 126, 196-196.	0.6	0
678	Clinical Relevance of Minimal Residual Disease Monitoring in NPM1 Mutated AML: A Study of the AML Study Group (AMLSCG). Blood, 2015, 126, 227-227.	0.6	0
679	The Novel FLT3-N676K Mutant Induces Acute Leukemia Independently of the Inv(16) Chimeric Gene CBFβ-MYH11. Blood, 2015, 126, 1383-1383.	0.6	0
680	Patient Derived Xenotransplantation Model of Atypical Chronic Myeloid Leukemia (aCML). Blood, 2015, 126, 2836-2836.	0.6	0
681	Phase I/II Study on Cytarabine and Idarubicin Combined with Escalating Doses of Clofarabine in Untreated Patients with Acute Myeloid Leukemia and High Risk for Induction Failure (AMLSCG 17-10) Tj ETQq1 1 0.784314 rgBT /Overl	0.6	0
682	Stable Silencing of RUNX1/ETO Induces Expression of a Shortened PU.1 Variant in t(8;21) Kasumi Cells. Blood, 2016, 128, 2716-2716.	0.6	0
683	Identification of Baseline Characteristics That Predict Good Outcome of Allogeneic Hematopoietic Cell Transplantation in Young Chronic Lymphocytic Leukemia Patients - a Retrospective Analysis from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. Blood, 2016, 128, 522-522.	0.6	0
684	Myeloablative Versus Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation for Secondary Acute Myeloid Leukemia in Patients with Prior Myelodysplastic Syndrome/ Myeloproliferative Disorders: An ALWP of EBMT Study. Blood, 2017, 130, 907-907.	0.6	0

#	ARTICLE	IF	CITATIONS
685	Active surveillance and deferred medical treatment (ASDT) in metastatic renal cell carcinoma (mRCC): Update of a single center experience and efficacy of medical treatment.. Journal of Clinical Oncology, 2018, 36, 4581-4581.	0.8	0
686	Synergy between FLT3-ITD and p53 Haploinsufficiency or Loss in the Development of Acute Myeloid Leukemia. Blood, 2018, 132, 771-771.	0.6	0
687	Outcome of Transformed Fanconi Anaemia Patients after Hematopoietic Stem Cell Transplantation: Analysis on Behalf of European Group for Blood and Marrow Transplantation. Blood, 2018, 132, 646-646.	0.6	0
688	Prognostic Value of Cpss Cytogenetic Risk Classification in Patients with CMML after Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Multicenter Study of the Chronic Malignancies Working Party of the EBMT. Blood, 2018, 132, 2182-2182.	0.6	0
689	Allogeneic Stem Cell Transplantation for Blast Crisis Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors â€” a Retrospective Study By the EBMT Chronic Malignancies Working Party. Blood, 2018, 132, 3465-3465.	0.6	0
690	Optimized Induction of Mitochondrial Apoptosis By Combination Therapies with Venetoclax for Chemotherapy-Free Treatment of BCR-ABL+ Acute Lymphoblastic Leukemia in Preclinical Models. Blood, 2018, 132, 4025-4025.	0.6	0
691	T Regulatory Cell Receptor Repertoire Focusing and Clonal Expansion Indicates Control of Acute GvHD after Donor Lymphocyte Infusion. Blood, 2018, 132, 822-822.	0.6	0
692	Focused Regulatory T Cell Repertoires Are Indicative of Successful GvHD Control in Experimental and Clinical Stem Cell Transplantation. Blood, 2018, 132, 2029-2029.	0.6	0
693	NKG2C+CD57+ Natural Killer Cells May Play an Important Role in Maintaining Virus-Specific Immune Reconstitution Post-Allogeneic HSCT. Blood, 2018, 132, 3327-3327.	0.6	0
694	Post-Transplant Cyclophosphamide Versus Antithymocyte Globulin in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation from One Antigen HLA-Mismatched Donors: A Retrospective Analysis from the Acute Leukemia Working Party of the EBMT. Blood, 2018, 132, 1016-1016.	0.6	0
695	CAR-T Cells Targeting gp350 Recognize Immortalized Cells Latently Infected with EBV. Blood, 2018, 132, 4540-4540.	0.6	0
696	Haploidentical Transplantation Using High Dose Post-Transplant Cyclophosphamide for Patients with Aplastic Anemia : The European Group for Blood and Marrow Transplantation Experience. Blood, 2018, 132, 486-486.	0.6	0
697	Signaling Pathways of Mutant IDH1 Independent of R-2-Hydroxyglutarate. Blood, 2018, 132, 2617-2617.	0.6	0
698	In Vivo Kinetics of Early, Hypomethylating Agent-Induced Methylome and Transcriptome Changes in Primary AML Blasts: Random or Specific?. Blood, 2018, 132, 3892-3892.	0.6	0
699	Slit-Robo Pathway Is Clinically Relevant and May Represent a Potential Target in Acute Promyelocytic Leukemia. Blood, 2018, 132, 1533-1533.	0.6	0
700	Functional Screening for Pathways Regulating Chemoresistance and Sensitivity in Leukemia Stem Cells. Blood, 2018, 132, 3933-3933.	0.6	0
701	The Impact of Cytogenetics on the Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed/Refractory Acute Myeloid Leukemia: A Survey from the Acute Leukemia Working Party (ALWP) of EBMT. Blood, 2018, 132, 4639-4639.	0.6	0
702	Prognostic Value of a New Clinically-Based Classification System in Patients with CMML Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Analysis of the EBMT Chronic Malignancies Working Party. Blood, 2018, 132, 4390-4390.	0.6	0

#	ARTICLE	IF	CITATIONS
703	Pembrolizumab Therapy Exacerbates EBV-Induced Infections and Tumors in a Long-Term Fully Humanized Mouse Model. <i>Blood</i> , 2018, 132, 2405-2405.	0.6	0
704	Metformin treatment Overcomes ATRA-Resistance in Acute Promyelocytic Leukemia and Increases FOXO3A Expression. <i>Blood</i> , 2018, 132, 1532-1532.	0.6	0
705	Prolyl Hydroxylase 3 (Phd3) Is a Therapeutic Target in Isocitrate Dehydrogenase 1 (IDH1) Mutated Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 759-759.	0.6	0
706	Assessment of the Genomic Landscape of Intermediate Risk Acute Myeloid Leukemia As Defined By 2010 ELN Risk Classification. <i>Blood</i> , 2018, 132, 994-994.	0.6	0
707	Measurable Residual Disease (MRD) Monitoring in Acute Myeloid Leukemia (AML) with t(8;21)(q22;q22.1) RUNX1-RUNX1T1 Identifies Patients at High Risk of Relapse: Results of the AML Study Group (AMLSC). <i>Blood</i> , 2019, 134, 2740-2740.	0.6	0
708	Clinical and Functional Studies Reveal That TP73 Isoforms Levels Are Associated with Prognosis and RA-Resistance in Acute Promyelocytic Leukemia. <i>Blood</i> , 2019, 134, 2719-2719.	0.6	0
709	NKG2C+CD57+ Natural Killer Cells May Play an Important Role in Maintaining Virus-Specific Immune Reconstitution Post-Allogeneic HSCT. <i>Blood</i> , 2019, 134, 1939-1939.	0.6	0
710	MN1 Expression Is an Independent Prognostic Marker in FLT3-Mutated Acute Myeloid Leukemia and Is Involved in the Resistance to FLT3 Inhibitors. <i>Blood</i> , 2019, 134, 1403-1403.	0.6	0
711	Hematologic Recovery from Venetoclax-Containing Regimens in Relapsed/Refractory Acute Myeloid Leukemia Patients Depending on Prior Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2019, 134, 1359-1359.	0.6	0
712	Arsenic Trioxide Abrogate MN1 Mediated RA-Resistance in Acute Promyelocytic Leukemia. <i>Blood</i> , 2019, 134, 5166-5166.	0.6	0
713	Efficacy of Chemotherapy, Phd-Inhibitor Molidustat or BRD4 Inhibitor JQ1 in Combination with Targeted Inhibition of Mutated IDH1 in Human AML In Vivo. <i>Blood</i> , 2019, 134, 3933-3933.	0.6	0
714	Survival in metastatic renal cell carcinoma (mRCC) patients over two decades: Does age matter?. <i>Journal of Clinical Oncology</i> , 2020, 38, e17103-e17103.	0.8	0
715	Transplant Outcomes in Patients with Ph+ Chronic Myeloid Leukemia: Haploidentical Donors Compared to Matched Sibling Donors and Matched/Mismatched Unrelated Donors: A Retrospective Analysis from the EBMT Chronic Malignancies Working Party (EBMT-CMWP). <i>Blood</i> , 2021, 138, 3959-3959.	0.6	0
716	Molecular Response Patterns in Relapsed/Refractory AML Patients Treated with Selinexor and Chemotherapy. <i>Blood</i> , 2021, 138, 2369-2369.	0.6	0
717	Clonal Relapse Dynamics in Acute Myeloid Leukemia Following Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2021, 138, 611-611.	0.6	0
718	Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia with Hyperdiploid Complex Karyotype: A Study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2021, 138, 3952-3952.	0.6	0
719	<i>IDH</i> Mutations Are Associated with an Increased Risk of Coronary Artery Disease and Cardiotoxicity in Patients with Established AML. <i>Blood</i> , 2020, 136, 32-33.	0.6	0
720	Mutational Landscape of Relapsed Core-Binding Factor Acute Myeloid Leukemia (CBF-AML). <i>Blood</i> , 2020, 136, 42-42.	0.6	0

#	ARTICLE	IF	CITATIONS
721	Allogeneic Hematopoietic Cell Transplantation in Patients with Therapy-Related Myeloid Neoplasm after Breast Cancer: A Study of the Chronic Malignancies Working Party of the EBMT. <i>Blood</i> , 2020, 136, 3-4.	0.6	0
722	P-175: Outcomes of autologous-allogeneic vs autologous tandem approach followed by thalidomide maintenance for transplant-eligible patients with newly diagnosed multiple myeloma: a prospective phase II-study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S132.	0.2	0
723	Long-term bone marrow culture data is the most powerful predictor for peripheral blood progenitor cell mobilization in healthy donors. <i>Haematologica</i> , 2005, 90, 294.	1.7	0
724	Chemotherapy-Free Targeted Anti-BCR-ABL+ Acute Lymphoblastic Leukemia Therapy May Benefit the Heart. <i>Cancers</i> , 2022, 14, 983.	1.7	0
725	MO343: Deep Analysis of The AKI–CKD in Allogeneic Stem Cell Transplantation–A Big Data Approach. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .	0.4	0